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Abstract: Die Prävalenz für eine Sensibilisierung gegenüber gewöhnlichen Allergenen, sowie die Häufigkeit
allergischer Krankheiten, wie Asthma, Rhinitis, atopischer Dermatitis und Lebensmittelallergien haupt-
sächlich in den ersten drei Lebensjahren, ist im Laufe der letzten 50 Jahre markant gestiegen. Allergische
Reaktionen sind gekennzeichnet durch ihre Produktion von IgE Antikörpern, Mastzellendegranulation
und Sekretion proinflammatorischer Moleküle. Die Entstehung von Allergien ist zu einem gewissen Teil
genetisch veranlagt. Es konnte jedoch bereits gezeigt werden, dass die Exposition verschiedener Umwelt-
faktoren, wie Mikroben oder Nahrungsmittelbestandteilen Kinder vor Allergien schützt, vor allem dann,
wenn die Exposition schon während der Schwangerschaft oder früh im Leben stattfand. Im ersten Teil
dieser Dissertation untersuchten wir den Einfluss früher pre- und postnataler Expositionen diverser bäuer-
lichen Umweltfaktoren auf die Genexpression verschiedener Rezeptoren des angeborenen Immunsystems
(Toll-like Rezeptoren und CD14). Toll-like Rezeptoren (TLRs) und CD14 erkennen konservierte Moleküle
von Mikroorganismen und lösen die Aktivierung des adaptiven Immunsystems aus. Wir konnten dabei
zeigen, dass bei Kindern, deren Mütter während der Schwangerschaft auf einem Bauernhof arbeiteten,
verschiedene TLRs im Nabelschnurblut teilweise signifikant stärker exprimiert waren als bei Kontrol-
lkindern. Die TLR-Genexpression nach einem Jahr war assoziiert mit Milchkonsum vom Bauernhof,
besonders mit ungekochter Milch. Insgesamt weisen die Resultate darauf hin, dass sowohl die Exposition
während der Schwangerschaft, als auch im ersten Lebensjahr die Expression von TLRs beeinflusst. Im
Weiteren analysierten wir den Zusammenhang zwischen TLR-Expression und der Entstehung atopischer
Dermatitis in den ersten zwei Lebensjahren. Bei Kindern, die in dieser Zeitspanne an einer atopischen
Dermatitis erkrankten, konnte eine signifikant tiefere Expression von TLR5 und TLR9 im Nabelschnur-
blut nachgewiesen werden. Schützend wirkte sich mütterlicher Kontakt während der Schwangerschaft
gegenüber Bauernhofexpositionen wie z.B. Tierkontakt aus, was möglicherweise auf eine Gen-Umwelt-
Interaktion schliessen lässt. Zu guter letzt fanden wir heraus, dass eine ergänzende mütterliche Vi-
tamin D Gabe während der Schwangerschaft in Zusammenhang mit einer erhöhten Genexpression der
immunglobulin-like transcripts (ILT)3 und ILT4 steht, beides Rezeptoren für tolerogene dentritische
Zellen, welche den Transkriptionsfaktor (NF)-￿B und die durch ihn induzierte Entzündungsantwort hem-
men. Diese Resultate deuten auf eine frühe Induktion einer toleranzbildenden Immunantwort durch Vi-
tamin D hin. Der zweite Teil dieser Arbeit beschäftigt sich mit der Problematik Lebensmittelallergien zu
behandeln, da die strikte Vermeidung allergieauslösender Lebensmittel immer noch die beste und einzige
Methode ist um ernste anaphylaktische Reaktionen zu unterbinden. Unsere Arbeit fokussierten wir dabei
auf die Desensibilisierung, eine Methode bei welcher die Menge des Allergens in steigenden Konzentra-
tionen über eine Zeitspanne verabreicht wird und die bereits in der Behandlung von Heuschnupfen und
Insektenstichallergien Anwendung findet. Wir verwendeten attenuierte, intrazellulär lebende Bakterien
(Salmonella enterica serovar Typhimurium) als Vektoren für die Freisetzung des Allergens im Darm. Die
Allergenproduktion mittels verschiedener Bakterienstämme und Regulationsmechanismen untersuchten
wir in vitro, während wir die Wirksamkeit unseres Konstruktes prophylaktisch und therapeutisch in einem
murinen Allergensensibilisierungsmodel austesteten. Nach kombinierter Einnahme von Mikroorganis-
men und Ausschüttung geringer Allergenmengen konnten abgeschwächte anaphylaktische Symptome und
erhöhte antigenspezifische IgA-Werte sowie reduzierte Genexpressionen verschiedener TLRs festgestellt
werden, was auf eine mögliche Eignung dieser Methode zur Prävention und/oder Behandlung von Lebens-
mittelallergien hindeutet. Die genauen molekularen Mechanismen bleiben allerdings weiterhin unklar und
es benötigt zusätzliche Untersuchungen in diesem Bereich. Over the last half century, the prevalence of
sensitization to common allergens has increased markedly as well as the incidence of allergic diseases like
asthma, rhinitis, atopic dermatitis and food allergies, mainly during the first three years of life. Allergic
reactions are characterized through production of IgE antibodies, mast cell degranulation and secretion
of proinflammatory molecules. The development of allergies is at least partly influenced by genetical
predispositions. However, it was already shown, that the exposition to various environmental factors
such as microbial or dietary components protect children against allergic diseases, mainly if the exposure
occurs during pregnancy or early in life. In the first part of this thesis we investigated various farming
exposition factors during pregnancy and first year of age on the expression of receptors of the innate
immunity (Toll- like receptors and CD14). Toll-like receptors (TLRs) and CD14 recognize conserved
molecules of microorganisms and trigger the induction of the adaptive immune response. We were able
to demonstrate that the expression of different TLRs in cord blood of children whose mothers worked on
a farm during pregnancy were partly significantly higher compared to non-farming newborns. The TLRs
expression at one year of age was associated with farm milk consumption, especially unboiled farm milk.
These results indicate that both, the pre- and early postnatal farming exposure influence the expression of
TLRs in children. Next, we analyzed the association between the gene expression of TLRs and CD14 and
the development of atopic dermatitis in the 2 first years of life. Children, suffering from atopic dermatitis
in the first two years of life have a significantly decreased expression of TLR5 and TLR9 in cord blood.
Maternal farming exposure such as contact to farm animals during pregnancy has a protective effect
on atopic dermatitis in the two first years of life, which may indicate a gene-environment interaction.
Finally, we found that maternal vitamin D supplementation during pregnancy was related to an increase
in the gene expression of immunglobulin-like transcripts (ILT)3 and ILT4, both receptors of tolerogenic
dentritic cells which inhibit the transcription nuclear factor (NF)-￿B and inflammatory responses. These
results may point towards an early induction of tolerogenic immune responses by vitamin D. The second
part of this thesis concerns the current major problem to treat food allergy, since strict avoidance of
allergenic food is still the best method to prevent severe anaphylactic reactions. We focused our work
on desensitization, a method where the amount of allergen is administrated increasingly over a period
of time and which finds appliance to treat hay fever or insect sting allergies. We used attenuated intra-
cellular living bacteria (Salmonella enterica serovar Typhimurium) as vector for allergen delivery in the
gut. The allergen production by different bacterial strains and regulation mechanisms was investigated in
vitro and the efficacy of our construct was tested prophylactically as well as therapeutically in a murine
allergen sensitization model. It could be demonstrated that the combined intake of microorganisms and
the release of low amounts of allergen reduced anaphylactic symptoms combined with increased antigen-
specific immunoglobulin A (IgA) titres and decreased gene expression of TLRs. This approach may be
a possible method to prevent or treat food allergies. However, the exact molecular mechanisms are still
unclear and further analyses have to be done.
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Zusammenfassung 
Die Prävalenz für eine Sensibilisierung gegenüber gewöhnlichen Allergenen, sowie die 
Häufigkeit allergischer Krankheiten, wie Asthma, Rhinitis, atopischer Dermatitis und 
Lebensmittelallergien hauptsächlich in den ersten drei Lebensjahren, ist im Laufe der letzten 
50 Jahre markant gestiegen. Allergische Reaktionen sind gekennzeichnet durch ihre 
Produktion von IgE Antikörpern, Mastzellendegranulation und Sekretion 
proinflammatorischer Moleküle. Die Entstehung von Allergien ist zu einem gewissen Teil 
genetisch veranlagt. Es konnte jedoch bereits gezeigt werden, dass die Exposition 
verschiedener Umweltfaktoren, wie Mikroben oder Nahrungsmittelbestandteilen Kinder vor 
Allergien schützt, vor allem dann, wenn die Exposition schon während der Schwangerschaft 
oder früh im Leben stattfand.   
 
Im ersten Teil dieser Dissertation untersuchten wir den Einfluss früher pre- und postnataler 
Expositionen diverser bäuerlichen Umweltfaktoren auf die Genexpression verschiedener 
Rezeptoren des angeborenen Immunsystems (Toll-like Rezeptoren und CD14). Toll-like 
Rezeptoren (TLRs) und CD14 erkennen konservierte Moleküle von Mikroorganismen und 
lösen die Aktivierung des adaptiven Immunsystems aus. Wir konnten dabei zeigen, dass bei 
Kindern, deren Mütter während der Schwangerschaft auf einem Bauernhof arbeiteten, 
verschiedene TLRs im Nabelschnurblut teilweise signifikant stärker exprimiert waren als bei 
Kontrollkindern. Die TLR-Genexpression nach einem Jahr war assoziiert mit Milchkonsum 
vom Bauernhof, besonders mit ungekochter Milch. Insgesamt weisen die Resultate darauf 
hin, dass sowohl die Exposition während der Schwangerschaft, als auch im ersten 
Lebensjahr die Expression von TLRs beeinflusst.  
 
Im Weiteren analysierten wir den Zusammenhang zwischen TLR-Expression und der 
Entstehung atopischer Dermatitis in den ersten zwei Lebensjahren. Bei Kindern, die in dieser 
Zeitspanne an einer atopischen Dermatitis erkrankten, konnte eine signifikant tiefere 
Expression von TLR5 und TLR9 im Nabelschnurblut nachgewiesen werden. Schützend 
wirkte sich mütterlicher Kontakt während der Schwangerschaft gegenüber 
Bauernhofexpositionen wie z.B. Tierkontakt aus, was möglicherweise auf eine Gen-Umwelt-
Interaktion schliessen lässt.  
 
Zu guter letzt fanden wir heraus, dass eine ergänzende mütterliche Vitamin D Gabe während 
der Schwangerschaft in Zusammenhang mit einer erhöhten Genexpression der 
immunglobulin-like transcripts (ILT)3 und ILT4 steht, beides Rezeptoren für tolerogene 
dentritische Zellen, welche den Transkriptionsfaktor (NF)-κB und die durch ihn induzierte 
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Entzündungsantwort hemmen. Diese Resultate deuten auf eine frühe Induktion einer 
toleranzbildenden Immunantwort durch Vitamin D hin. 
 
Der zweite Teil dieser Arbeit beschäftigt sich mit der Problematik Lebensmittelallergien zu 
behandeln, da die strikte Vermeidung allergieauslösender Lebensmittel immer noch die 
beste und einzige Methode ist um ernste anaphylaktische Reaktionen zu unterbinden. 
Unsere Arbeit fokussierten wir dabei auf die Desensibilisierung, eine Methode bei welcher 
die Menge des Allergens in steigenden Konzentrationen über eine Zeitspanne verabreicht 
wird und die bereits in der Behandlung von Heuschnupfen und Insektenstichallergien 
Anwendung findet.  
Wir verwendeten attenuierte, intrazellulär lebende Bakterien (Salmonella enterica serovar 
Typhimurium) als Vektoren für die Freisetzung des Allergens im Darm. Die 
Allergenproduktion mittels verschiedener Bakterienstämme und Regulationsmechanismen 
untersuchten wir in vitro, während wir die Wirksamkeit unseres Konstruktes prophylaktisch 
und therapeutisch in einem murinen Allergensensibilisierungsmodel austesteten.  
Nach kombinierter Einnahme von Mikroorganismen und Ausschüttung geringer 
Allergenmengen konnten abgeschwächte anaphylaktische Symptome und erhöhte 
antigenspezifische IgA-Werte sowie reduzierte Genexpressionen verschiedener TLRs 
festgestellt werden, was auf eine mögliche Eignung dieser Methode zur Prävention und/oder 
Behandlung von Lebensmittelallergien hindeutet. Die genauen molekularen Mechanismen 
bleiben allerdings weiterhin unklar und es benötigt zusätzliche Untersuchungen in diesem 
Bereich.  
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Summary 
Over the last half century, the prevalence of sensitization to common allergens has increased 
markedly as well as the incidence of allergic diseases like asthma, rhinitis, atopic dermatitis 
and food allergies, mainly during the first three years of life. Allergic reactions are 
characterized through production of IgE antibodies, mast cell degranulation and secretion of 
proinflammatory molecules. The development of allergies is at least partly influenced by 
genetical predispositions. However, it was already shown, that the exposition to various 
environmental factors such as microbial or dietary components protect children against 
allergic diseases, mainly if the exposure occurs during pregnancy or early in life. 
 
In the first part of this thesis we investigated various farming exposition factors during 
pregnancy and first year of age on the expression of receptors of the innate immunity (Toll-
like receptors and CD14). Toll-like receptors (TLRs) and CD14 recognize conserved 
molecules of microorganisms and trigger the induction of the adaptive immune response.  
We were able to demonstrate that the expression of different TLRs in cord blood of children 
whose mothers worked on a farm during pregnancy were partly significantly higher compared 
to non-farming newborns. The TLRs expression at one year of age was associated with farm 
milk consumption, especially unboiled farm milk. These results indicate that both, the pre- 
and early postnatal farming exposure influence the expression of TLRs in children.  
 
Next, we analyzed the association between the gene expression of TLRs and CD14 and the 
development of atopic dermatitis in the 2 first years of life. Children, suffering from atopic 
dermatitis in the first two years of life have a significantly decreased expression of TLR5 and 
TLR9 in cord blood. Maternal farming exposure such as contact to farm animals during 
pregnancy has a protective effect on atopic dermatitis in the two first years of life, which may 
indicate a gene-environment interaction. 
 
Finally, we found that maternal vitamin D supplementation during pregnancy was related to 
an increase in the gene expression of immunglobulin-like transcripts (ILT)3 and ILT4, both 
receptors of tolerogenic dentritic cells which inhibit the transcription nuclear factor (NF)-κB 
and inflammatory responses. These results may point towards an early induction of 
tolerogenic immune responses by vitamin D.  
 
 
The second part of this thesis concerns the current major problem to treat food allergy, since 
strict avoidance of allergenic food is still the best method to prevent severe anaphylactic 
reactions. We focused our work on desensitization, a method where the amount of allergen 
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is administrated increasingly over a period of time and which finds appliance to treat hay 
fever or insect sting allergies.  
We used attenuated intracellular living bacteria (Salmonella enterica serovar Typhimurium) 
as vector for allergen delivery in the gut. The allergen production by different bacterial strains 
and regulation mechanisms was investigated in vitro and the efficacy of our construct was 
tested prophylactically as well as therapeutically in a murine allergen sensitization model. 
It could be demonstrated that the combined intake of microorganisms and the release of low 
amounts of allergen reduced anaphylactic symptoms combined with increased antigen-
specific immunoglobulin A (IgA) titres and decreased gene expression of TLRs. 
This approach may be a possible method to prevent or treat food allergies. However, the 
exact molecular mechanisms are still unclear and further analyses have to be done.  
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Introduction 
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Chapter overview 
The human body has a tremendous capability for defence against invasion by foreign agents 
through its immune system. It is composed of a less specific and a more specific type of 
immunity, innate and adaptive immunity. The adaptive immunity is characterized through 
lymphocytes (B- and T-cells) producing various types of antigen receptors through gene-
rearrangement. These cells show clonal expansion when stimulated with a specific antigen 
and exhibit immunological memory leading to a heightened state of immune reactivity after a 
second encounter with the same antigen. However it takes several days until the cells are 
able to combat invading pathogens. Therefore, the host organism has the innate immune 
system, which is phylogenetically conserved and present in almost all multicellular 
organisms. It provides the first line of defence before adaptive immunity is activated. This 
chapter should deliver insights into the interaction between both immune branches and the 
complexity behind them. Furthermore, the development of allergic disorders and their 
influencing factors are pointed out. 
 
The innate immune system 
Pattern recognition receptors 
The innate immune recognition is mediated by a set of germline encoded non-clonal 
receptors which belong to several distinct protein families1. These receptors recognize 
conserved microbe-specific molecular structures, which are called pathogen-associated 
molecular patterns (PAMPs), and are therefore, referred as pattern recognition receptors 
(PRRs). PRRs can recognize PAMPs directly, through membrane-bound or cytoplasmic 
receptors or indirectly, whereby soluble PRRs coat or opsonize the pathogen3. Recognition 
of PAMPs by PRRs can directly activate effector mechanisms of innate immunity, such as 
phagocytosis, induction of synthesis of antimicrobial peptides, and induction of nitric oxide 
synthase in macrophages. Additionally, expression of inflammatory and effector 
cytokines/chemokines is induced by PAMPs, leading to recruitment of leukocytes to the sites 
of infection as well as stimulation and participation of the adaptive immune system in 
elimination of the pathogen. Finally, recognition of PAMPs by PRRs induces the expression 
of co-stimulatory molecules on antigen-presenting cells (APCs)1,4. 
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Toll-like receptors 
Toll-like receptors (TLRs) are one group of PRRs 
which recognize highly conserved microbial 
structures and thereby initiate an immune 
response. The discovery of the TLR familiy began 
with the isolation of Drosophila Toll, which had 
initially been identified as having a role in 
embryonic dorso-ventral patterning5 but is also an 
essential factor in the insect innate immune 
response against fungal infection6. Ten different 
homologues of Toll were identified through 
database searches in humans (TLR1-TLR10) and 
twelve TLRs in mice (TLR1-9, TLR11-13)2,7. Each 
of them recognizes specific components found on 
bacteria and viruses (Table 1). They are 
structurally similar transmembrane PRRs with a 
cytoplasmic and an extracellular portion (Fig. 1). 
The cytoplasmic domain shows high similarity to 
that of the mammalian IL-1 receptor and is called 
Toll/IL-1 receptor (TIR) domain. The TIR domain consists of three conserved boxes (Box 1-
3), which are crucial for signalling. By contrast, the extracellular domain of the IL-1 receptor 
and TLRs differs markedly: The extracellular domain of TLRs consist of leucine-rich repeats 
(LRRs) whereas the IL-1 receptors possess an Ig-like domain2. TLRs are differentially 
expressed on a wide range of immune cells including T- and B-lymphocytes, dendritic cells, 
macrophages and neutrophiles, as well as on non-immune cells, such as fibroblast cells, 
epithelial cells and keratinocytes8,9. TLR 1, 2, 4, 5, and 6 are located on the cell surface and 
are mainly responsible for the detection of bacterial products, whereas the subset of TLRs 
that sense nucleic-acid-like structures (TLRs 3, 7, 8 and 9) are expressed intracellularly on 
endosomal membranes2,10. 
 
 
 
Figure 1.: Schematic structure of Toll-like receptor (TLR) 
and IL-1 receptor (IL-1R). Both receptors have a 
conserved intracellular Toll/IL-1 receptor (TIR) domain, 
characterized by the presence of three highly 
homologues regions (Box 1-3). TLRs have a leucine-
rich, extracellular domain, whereas IL-1Rs have 
immunoglobulin (Ig)- like domain. Adapted from2. 
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Table 1 | Pattern recognition receptors in humans    
   
Receptor  Ligand Origin of ligand  
TLR1  Triacyl lipopeptides Bacteria and mycobacteria  
 Soluble factors Neisseria meningitidis  
TLR2  Lipoprotein/lipopeptides Various pathogens  
 Peptidoglycan Gram-positive bacteria  
 Lipoteichoic acid Gram-positive bacteria  
 Lipoarabinomannan Mycobacteria  
 Phenol-soluble modulin Staphylococcus epidermidis  
 Glycoinositolphospholipids Trypanosoma cruzi  
 Glycolipids Treponema maltophilum  
 Porins Neisseria  
 Atypical lipopolysaccharide Leptospira interrogans  
 Atypical lipopolysaccharide Porphyromonas gingivalis  
 Zymosan  Fungi  
 Heat-shock protein 70 Host  
TLR3  Double-stranded RNA Viruses  
TLR4  Lipopolysaccharide Gram-negative bacteria  
 Taxol Plants  
 Fusion protein  Respiratory syncytial virus  
 Envelope protein  Mouse mammary-tumour 
virus  
 Heat-shock protein 60 Chlamydia pneumoniae  
 Heat-shock protein 70  Host  
 Type III repeat extra domain A of 
fibronectin  
Host  
 Oligosaccharides of hyaluronic acid  Host  
 Polysaccharide fragments of heparan 
sulphate  
Host  
 Fibrinogen  Host  
TLR5  Flagellin Bacteria  
TLR6  Diacyl lipopeptides  Mycoplasma  
 Lipoteichoic acid Gram-positive bacteria  
 Zymosan Fungi  
TLR7  Imidazoquinoline Synthetic compounds  
 Loxoribine Synthetic compounds  
 Bropirimine Synthetic compounds  
 Single-stranded RNA Viruses  
TLR8  Imidazoquinoline Synthetic compounds  
 Single-stranded RNA Viruses  
TLR9  CpG-containing DNA Bacteria and viruses  
TLR10  Not determined  Not determined 
NOD-1  Peptidoglycan Gram-negative and few gram-positive bacteria 
NOD-2  Muramyl dipeptides Gram-positive/negative bacteria  
Adapted from2 
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TLR1, TLR2, TLR6 
TLR2 recognizes the largest number of ligands of the mammalian TLRs. The list includes 
lipoproteins from a variety of pathogens, lipoteichoic acid from Gram-positive bacteria, 
lipoarabinomannan from mycobacteria, glycosylphophatidylinositol anchors from 
Trypanosoma cruzi, a phenol-soluble modulin from Staphylococcus epidermis, zymosan from 
fungi and glycolipids from Treponema maltophilum11,12. The mechanisms by which TLR2 
recognizes an increased repertoire of microbial components is now known by the fact that 
TLR2 forms heterodimers with either TLR1 or TLR613,14.  
 
TLR4 and CD14 
TLR4 was the first human TLR identified to play an essential role in recognition of 
lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative 
bacteria. However, the response to LPS requires several additional molecules. LPS binds to 
LPS-binding protein (LBP), an acute-phase protein in serum produced by hepatocytes and 
this complex associates with CD14. CD14 is viewed also as pattern recognition receptor15 
which is able to interact not only with LPS but with various bacterial products, including 
lipoarabinomannan from Mycobacterium tuberculosis15, peptidoglycan from Staphylococcus 
aureus16, mannuronic acid polymers from Pseudomonas aeruginosa17, rhamnose-glucose 
polymers from Streptococcus mutans18, and chitosans from arthropods19. CD14 exists in a 
membrane bound (mCD14) and a soluble (sCD14) form. mCD14 is a glycosyl-
phosphatidylinositol (GPI)-linked glycoprotein, expressed on monocytes/macrophages and 
neutrophiles20, whereas sCD14 is found in human plasma21 and has the ability to stimulate 
CD14-negative cells, such as endothelial cells, astrocytes, and epithelial cells22.  
Another protein involved in the response to LPS is MD-2, that binds both the extracellular 
domain of TLR4 and the hydrophobic portion of LPS3. MD-2 has been shown to be essential 
for surface expression of TLR4, and therefore mediated the responsiveness to LPS23,24. An 
additional molecule involved in the recognition of LPS is RP105, preferentially expressed in 
B-cells. RP105 bears leucine-rich repeats that are structurally related to TLRs in the 
extracellular domain.  
 
TLR5 
TLR5 recognizes a conserved domain of flagellin, a subunit of the flagellar structure, present 
in many different bacteria like Salmonella or Legionella.  
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This receptor is expressed on the basolateral but not on the apical side of the intestinal 
epithelial cells25 as well as on lung epithelial cells26 and has an important role in microbial 
recognition at the mucosal surface.  
 
TLR3, 7, 8, 9 
TLR3, 7, 8 and 9 are all located in the endosomal membrane2 and are involved in the 
recognition of nucleic-acid-like structures. TLR7 and 8 are essential for the recognition of 
guanosine- or uridine-rich single-stranded RNA (ssRNA) from viruses27, whereas TLR9 
recognizes unmethlyated Cytosin-phosphatidyl-Guanosin (CpG) motifs present in bacterial 
and viral DNA28. TLR3 is involved in recognition of double-stranded RNA (dsRNA)29, which is 
produced by most viruses during their replication.  
 
TLR10 
The specific ligands for TLR10 are currently unknown. However, protein complexes with 
TLR10 have been found as homodimer and heterodimers, associated with TLR1 or TLR2. 
The expression seems to be restricted to B-cells and plasmacytoid dendritic cells (PDCs), 
similar to TLR7 and TLR9, indicating a related role of TLR7, TLR9 and TLR10 in terms of 
biological functions30. 
 
Nucleotide-binding oligomerization domain (NOD)-like receptors 
Nod-like receptors (NLRs) are a family of intracellular sensors that play key roles in innate 
immunity and inflammation31. These proteins have been identified at first on the basis of their 
homology with the plant R proteins, which is a large family of proteins that mediate 
antipathogen responses in plants32. The human NLR family has 23 members and there are at 
least 34 NLR genes in mice3,33. The structure of NLR proteins is tripartite. First, a variable N-
terminal protein–protein interaction domain, defined by the caspase recruitment domain 
(CARD), pyrin domain (PYD), or the baculovirus inhibitor domain (BIR), second, a centrally 
located NOD domain that facilitates self-oligomerization during activation and third, a C-
terminal leucine-rich repeat (LRR) responsible for binding and detecting PAMPs34.  
 
NOD1 and NOD2 
NOD1 and NOD2 can be viewed as the ‘germinal’ and the best characterized members of the 
NLR family3,33. NOD1 is ubiquitously expressed and recognizes a specific core motif of 
peptidoglycans of Gram-negative, but only a few strains of Gram-positive bacteria35,36. In 
comparison, NOD2 expression is restricted to monocytes, macrophages, dendritic cells, and 
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intestinal Paneth cells and peptidoglycan muramyl dipeptide of all Gram-positive and Gram-
negative bacteria are detected by this receptor37. 
 
TLR signalling pathway 
After ligand binding, TLRs dimerize and undergo a conformational change in the cytoplasmic 
TIR domains, creating a new platform on which to build a signalling complex. Via TIR-TIR 
interactions different adaptor proteins are recruited, including myeloid differentiation primary 
response 88 protein (MyD88), TIR-containing adaptor protein/MyD88-adaptor-like 
(TIRAP/MAL), TIR-containing adaptor inducing interferon-β (IFN-β)/TIR-domain-containing 
adaptor molecule 1 (TRIF/TICAM1) and TIR-domain-containing adaptor molecule/TRIF-
related adaptor molecule 2 (TRAM/TICAM2) and sterile α- and armadillo-motif containing 
protein (SARM)7,9. Similar to the TLRs, the adaptors are conserved across many species38,39. 
Subsequent recruitment of downstream signalling molecules leads to activation of nuclear 
factor-κB (NF-κB) transcription factors, as well as the mitogen-activated protein kinases 
(MAPKs), extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase 
(JNK)40. 
The resulting signalling pathways may generally be grouped into MyD88-dependent and 
MyD88-independent/TRIF-dependent pathways. 
 
MyD88-dependent pathway 
MyD88-dependent signalling pathway is shared by all members of the TLR family except 
TLR3 and results in the induction of a core set of responses. MyD88 was first shown to be 
involved in signalling by the type 1 IL-1 receptor (IL-1R1)41. MyD88 comprises a C-terminal 
TIR domain and a N-terminal death domain (DD), separated by a small intermediate domain 
(ID)42. After TLR stimulation MyD88 is recruited to the cytoplasmic portion of the TLR and 
interacts with the death domains of members of the IRAK (IL-1 receptor-associated kinase) 
family of protein kinases, including IRAK1, IRAK2, IRAK4 and IRAK-M. IRAK4 is initially 
activated and in turn phosphorylates and activates IRAK1 which subsequently interacts with 
TNFR-associated factor-6 (TRAF6), leading to oligomerization and activation of 
TRAF67,9,41,43. Phosphorylated IRAK1 and TRAF6 then dissociate from the receptor and form 
a complex with TAK1 (transforming-growth-factor-activated kinase), TAB1 (TAK1-binding 
protein 1) and TAB2 at the plasma membrane, which induces the phosphorylation of TAB2 
and TAK1. IRAK1 is degraded at the plasma membrane, and the remaining complex 
(consisting of TRAF6, TAK1, TAB1 and TAB2) translocates to the cytosol, where it 
associates with the ubiquitin ligases UBC13 (ubiquitin-conjugating enzyme 13) and UEV1A 
(ubiquitin-conjugating enzyme E2 variant 1). Thereby TRAF6 is ubiquitinylated and induces 
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the activation of TAK1. TAK1, in turn, 
phosphorylates both mitogen-activated protein 
(MAP) kinases and the IKK complex (inhibitor of 
nuclear factor-B (IB)-kinase complex). This 
complex consists of IKK-α, IKK-β and IKK-
γ/NEMO (NF-κB essential modifier) and 
phosphorylates IκBs (NF-κB inhibitors), resulting 
in its ubiquitination and subsequent proteosome-
mediated degradation. This releases NF-κB, 
which moves to the nucleus and regulates its 
target genes, including those that encode 
proinflammatory cytokines7,9,41,43. 
Beside the participation of MyD88 in the 
activation of mitogen-activated protein kinase 
(MAPK) pathway7,9,41,43 it is also involved in the 
activation of several transcription factors of the 
interferon-regulatory factor (IRF) family, namely, 
IRF1, IRF7 and IRF57. IRF5 is involved in the 
induction of proinflammatory cytokines and type 
I interferones (IFNs) by all TLRs tested44. 
Activated TLR7 or TLR9 of plasmacytoid 
dentritic cells (pDCs) lead to activation of a 
MyD88 which directly interacts with IRF7, an 
essential transcription factor for IFN-α/β 
induction45,46. A simplified illustration of the 
MyD88-dependent pathway is depicted in Figure 
2. 
Figure 2. Stimulation of TLRs triggers the association 
of MyD88, which in turn recruits IRAK4, thereby 
allowing the association of IRAK1. TRAF6 is also 
recruited to the receptor complex, by associating with 
phosphorylated IRAK1. Phosphorylated IRAK1 and 
TRAF6 then dissociate from the receptor and form a 
complex with TAK1, TAB1 and TAB2 at the plasma 
membrane (not shown), which induces the 
phosphorylation of TAB2 and TAK1. IRAK1 is 
degraded at the plasma membrane, and the 
remaining complex (consisting of TRAF6, TAK1, 
TAB1 and TAB2) translocates to the cytosol, where it 
associates with the ubiquitin ligases UBC13 and 
UEV1A. This leads to the ubiquitylation of TRAF6, 
which induces the activation of TAK1. TAK1, in turn, 
phosphorylates both mitogen-activated protein (MAP) 
kinases and the IKK complex (inhibitor of nuclear 
factor-κB (IκB)-kinase complex), which consists of 
IKK-α, IKK-β and IKK-γ. The IKK complex then 
phosphorylates IκB, which leads to its ubiquitylation 
and subsequent degradation. This allows NF-κB to 
translocate to the nucleus and induce the expression 
of its target genes. Adapted from 2. 
 
TLRs, except TLR3 
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MyD88-independent/TRIF-dependent pathway 
As described above, the adaptor protein MyD88 is not 
required for NF-κB activation by TLR3. The TIR-domain-
containing adaptor molecule (TRIF) was shown to be 
essential for TLR3 as well as TLR4 mediated activation 
of interferon (IFN)-regulatory factor 3 (IRF3) in a MyD88 
independent manner47. TRIF interacts with receptor-
interacting protein 1 (RIP1) and also with TRAF3, which 
bridges to TBK1 and IKK-related proteins – IKKε (also 
known as inducible IKK, IKKi)48. TLR4 mediated MyD88-
independent IRF3 activation and interferon β (IFN-β) 
production needs in addition to TRIF also TRAM as 
adaptor molecule49. The activation of IRF3 by signalling 
through TLR4 is less rapid and potent compared to TLR3 
signalling, leading to decreased IFN-β production2 (Fig. 
3).  
 
 
 
 
 
 
Other molecules involved in TLR signalling 
Negative regulators of TLR signalling 
Inflammatory cytokine production through activation of TLR signalling has to be controlled, 
otherwise severe systemic disorders are elicited, such as endotoxic shock reaction, induced 
by TLR4/lipopolysaccarid (LPS) binding. Therefore, the organisms have evolved 
mechanisms which modulate the TLR-mediated response. Some of these negative 
regulators are shown in Figure 4 and discussed briefly here. 
 
MyD88 short (MyD88s) 
MyD88s is an alternative spliced variant of MyD88, the most crucial adaptor in TLR 
signalling, that lacks the interdomain. While MyD88 is ubiquitously expressed, MyD88s was 
CD14 
NF-κB 
NF-κB-binding motif 
Figure 3. MyD88-independent 
signalling pathway. The TIR 
domain-containing adaptor molecule 
TRIF is recruited to TLR3 and 4 
after ligand binding. TLR4 requires 
additionally the adaptor protein 
TRAM. Downstream of TRIF, IRF3 
is activated through the IKK/TBK1 
complex. Adapted from2 
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only detected in the spleen and, less strongly, in the brain. It was shown that MyD88s is not 
able to bind IRAK4 because of the missing intermediary domain and does not induce IRAK1 
phosphorylation, indicating that MyD88s is a member of the negative-feedback regulatory 
system2,50,51.  
 
IRAK-M and IRAK-2 
IRAK-2 and IRAK-M are members of the 
IRAK family that lack active 
serine/threonine kinases. IRAK-2 is 
expressed ubiquitously, whereas the 
expression of IRAK-M is restricted to 
monocytes and macrophages and 
upregulated following stimulation with TLR 
ligands. IRAK-M negatively regulates 
TLR-signalling pathways by preventing the 
dissociation of the IRAK1-IRAK4 complex 
from MyD88. Consequently the IRAK1-
TRAF6 complex does not form50,51. Four 
isoforms of murine IRAK-2 are known 
(IRAK2a-IRAK2d) generated by 
alternative splicing at the 5`end of the 
gene. Overexpression of IRAK2c and 
IRAK2d in fibroblasts inhibits LPS-
induced NF-κB activation in a dose-
dependant manner52. Furthermore 
treatment of murine macrophages with 
LPS induces the expression of IRAK2c 
indicating a possible negative feedback 
effect on the signalling pathway50,53. 
 
SOCS1 
SOCS1 is a member of the suppressor of cytokine signalling (SOCS) family of proteins, 
which are induced by cytokines and are involved in a negative feedback loop of cytokine 
signalling. Eight members of the SOCS family are identified (SOCS1-7 and Cytokine-
inducing SH2-containing protein (CIS)) and all of them are characterized through an amino-
terminal region of variable length, a central SH2 domain and a carboxy-terminal SOCS box. 
Figure 4. Intracellular Toll-like receptor regulators. TLR 
signalling pathways are tightly regulated by endogenous 
regulators at multiple levels. TRIAD3A promotes 
ubiquitylation and degradation of certain TLRs, whereas 
MyD88s (the short form of MyD88) antagonizes MyD88 
functions. Inhibitory proteins such as SOCS1 (suppressor of 
cytokine signalling 1), IRAKM (Toll-interacting protein), 
IRAK2c and IRAK2d selectively suppress IRAK function by 
targeting various stages of the TLR signalling pathways. 
Phosphatidylinositol 3-kinase (PIK3K) negatively regulates 
some TLR responses through an as-yet-unknown 
mechanism. A20 deubiquitylates TRAF6 (tumour-necrosis 
factor-receptor-associated factor 6) and affects both MyD88-
dependent and MyD88-independent pathways. NOD2 might 
inhibit TLR2 signalling by suppressing nuclear factor-κB (NF-
κB) activity. Adapted from Liew F. et al.; Nature (2005), 5. 
446-458. 
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SOCS1 and SOCS3 have additional a kinase inhibitory domain (KIR) and both act in a 
similar manner. SOCS1 is one of the best characterized proteins of the SOCS family, but the 
precise mechanism by which SOCS1 inhibits TLR signalling is still unclear. SOCS1 
expression is induced by cytokines that signal through JAK/STAT molecules but also after 
stimulation with LPS and CpG-containing DNA. In vivo studies have shown that SOCS1-
deficient mice are hypersensitive to LPS-induced endotoxic shock, leading to increased 
production of inflammatory cytokines. Furthermore, LPS tolerance is not induced in SOCS1 
deficient mice and LPS-induced IκB and p38 phosphorylation are upregulated in SOCS1 
deficient macrophages53,54. Children growing up on a farm, in an environment rich in 
microbes show an upregulation of SOCS1 expression compared to their peers not living on a 
farm55. Furthermore higher expression of SOCS1 gene is associated with reduced IgE and 
IFN-γ production55. However, a recent epidemiological study show that SOCS1 correlates 
with Th2 development and a higher risk for allergic sensitization56.  
 
ST2 
ST2, also known as T1, Fit-1 or DER4, is a TIR-containing orphan receptor, which is involved 
in the negative regulation of TLR signalling. Two main forms of ST2 exist: ST2L and sST2 
which are generated by alternative splicing of pre-mRNA. ST2L is a type I transmembrane 
protein characterized through three extracellular immunoglobulin-like domains and an 
intracellular TIR domain. The extracellular domain of sST2 is similar to the one of ST2L but 
the transmembrane and intracellular Toll-interleukin-1 receptor domains lack. sST2 is 
present in haematopoietic and non-haematopoietic cells, whereas ST2L is mainly expressed 
by cells of the major haematopoietic organs57-59 preferentially in murine and human Th2 but 
not Th1 cells60,61. Therefore, ST2L can be used as a specific marker for Th2 cells in in vitro 
experiments62. On the other hand, sST2 is present in normal human serum and elevated in 
asthmatic disease63. However, therapeutic experiments indicate that sST2 negatively 
regulates TH2 cell-mediated immunological responses, in contrast to ST2L64,65. Furthermore, 
gene expression analyses have shown that sST2 is at lower levels expressed in children 
exposed to microbial components and this, in turn, is associated with reduced T helper cell 
activation, lower IgE levels in serums, and hay fever66. It is currently unknown how sST2 
influences the TLR signalling cascade negatively but in vitro and in vivo analysis have shown 
that sST2 is able to downregulate mRNA expression of TLR4 and TLR1 in LPS-activated 
macrophages67 and suppresses the activation of NF-κB as well as the production of TH2 
cytokines in IL-33 signalling68.  
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Single immunoglobulin IL-1R-related molecule (SIGIRR) 
SIGIRR, also known as Toll–IL-1 receptor 8 (TIR8), is an orphan receptor like ST2L and 
characterized by a single extra-cellular immunoglobulin domain and a cytoplasmic TIR 
domain69. It has been identified as a negative regulator for IL-1R70, TLR471, and TLR9 
signalling70,72. Mice, lacking SIGIRR, develop more severe inflammatory responses to IL-1 
and show increased susceptibility to endotoxin shock51,53. The detailed molecular 
mechanisms by which SIGIRR suppresses TLR function are currently unknown but in vitro 
analysis has shown that SIGIRR can interact with TLR4, IRAK and TRAF651,73. 
 
TNF-related apoptosis-inducing ligand receptor (TRAILR) 
TRAILR is a receptor, which belongs to the TNF superfamily and binds TRAIL, also referred 
as Apo-2L. TRAILR-deficient macrophages stimulated by ligands for TLR2, TLR3 and TLR4, 
express high levels of TRAIL and show enhanced cytokine production. The inhibitory effect 
of TLR signalling seems to function by stabilizing the IκB subunit IκBα and therefore 
decreasing the nuclear translocation of NF-κB51.  
 
Phosphoinositide 3-kinase (PI3K) 
PI3K is a heterodimer that consists of a p85 regulatory subunit and a p110 catalytic chain, 
both necessary for PI3K activation. The activation of PI3K occurs through binding of 
microbial stimuli such as LPS, CpG DNA or CpG ODN (oligodeoxynucleotide) and plays an 
important role in regulating immune cell defensive mechanisms, including cytokine 
production, phagocytosis, and apoptosis. PI3K seems to have a positive and a negative 
influence on TLR signalling depending on the immune cell type and the TLR ligand used74. 
Different PI3K catalytic subunit isoforms exist which partly are involved in allergic airway 
inflammation and hyperresponsiveness. Therefore PI3K is dealt as a potential target for 
asthma treatment75. 
 
A20 
A20 is a 90-kDa zinc-finger protein which is activated by a variety of stimuli including 
synthetic RNA (poly I:C), LPS, and TNF-α76. A20 deficient mice injected with TNF-α show 
severe inflammation and elevated sensitivity to endotoxin shock, due to persistent activation 
of NF-κB77. Furthermore, A20 was shown to cleave the essential ubiquitin chain for 
downstream signalling of TRAF678, indicating that A20 is the only negative regulator that 
control MyD88-dependent as well as MyD88-independent TLR-signalling pathways51,78.  
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SHP2 
The tyrosine phosphatase SHP2 (SRC homology 2 (SH2)-domain-containing protein) has 
recently been shown to dephosphorylate STAT179 and negatively regulates the TRIF-
dependent, but not MyD88-dependent interferon and proinflammatory cytokine production80. 
 
TRIAD3A 
TRIAD3A is the most abundant alternatively spliced form of the TRIAD3 family and is a 
RING-finger E3 ligase. It was shown that TRIAD3A binds the cytoplasmic TIR domains of 
TLR4 and TLR9 and promotes their ubiquitylation and degradation, leading to a negative 
regulation of TLR mediated immune response81. 
 
NOD2 
As described before, nucleotide oligomerization domain (NOD)-like receptor 2 is a pattern 
recognition receptor, which recognizes the bacterial product muramyl dipeptide (MDP), a 
derivative of bacterial peptidoglycan82. MDP was found to suppress TLR2-ligand-induced T-
helper cell type 1 (Th1-cell) responses in wild-type, but not in NOD2-deficient mice, indicating 
that NOD2 is a negative regulator of TLR2 signalling51. However, results from human studies 
could not confirm this observation but suggest a synergistic effect between NOD2 and TLR2 
in a dose dependent manner83. 
 
TOLLIP 
The Toll-interacting protein (TOLLIP) serves as a negative regulator in innate immune 
response. TOLLIP interact with several members of the TIR superfamily, including TLR2 and 
TLR484 and is able to inhibit TLR2- and TLR4-mediated NF-κB activation, if it is over-
expressed84,85. The exact molecular mechanism of TOLLIP is not known. It has been shown 
that IRAK1 interacts with TOLLIP leading to phosphorylation of TOLLIP86. It is not clarified, if 
this phosphorylation step results in ubiquitinylation of IRAK1 and its subsequent degradation 
which might lead to the release of TOLLIP and its negative regulation51. In opposite to many 
other inflammation suppressors including IRAK-M, MyD88s, TOLLIP is constitutively 
expressed and also present in unstimulated cells together with other binding partners, 
suggesting that the function of TOLLIP is of more multifaceted nature87.  
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Innate immune recognition and activation of adaptive immunity 
Unlike innate immunity, the adaptive immunity has a high antigenic specificity, capable to 
recognize a tremendous number of diverse structures on foreign antigens, exhibits 
immunological memory and distinguishes self from nonself. The signals to activate this 
branch of the immune system are provided by antigen presenting cells (e.g. macrophages, 
dendritic cells, microglia, B-cells) after recognition of bacterial and viral components by 
receptors of the innate immunity (e.g. TLRs). The antigen binding leads to antigen uptake 
and processing. The degraded peptides are bound to MHC (major histocompatibility 
complex) class II molecules and presented to CD4+ T-lymphocytes leading to activation and 
expansion of CD4+ T-cells88.  
 
MHC molecules 
There are three classes of MHC molecules (MHCI, MHCII, MHCIII) encoded by different 
gene regions. The genes for MHCII are organized in the DP, DQ, and DR regions. MHCI and 
MHCII are membrane-bound glycoproteins that contain extracellular domains, a 
transmembrane segment, and a cytoplasmic anchor segment. Both are involved in antigen 
processing and presentation. In contrast, MHCIII genes encode various proteins that have 
immune functions, including tumor necrosis factor (TNF) or the complement components C4, 
C2, and factor B. MHCII molecules contain a 33 kDa α-chain and a 28 kDa β-chain, 
associated by noncovalent interactions4. The MHCII production is regulated at the level of 
transcription by CIITA (class II transactivator), which interact synergistically with the MHCII 
transcription factors regulatory factor X (RFX) 5, RFX associated ankyrin-containing protein 
(RFXANK), RFX-associated protein (RFXAP), nuclear factor binding to the Y box (NF-YB 
and NF-YB), and X2-box binding factor cyclic-AMP-responsive-element-binding (CREB) 
protein, referred as MHCII enhanceosome89. The transcription factors are more or less 
ubiquitously expressed whereas CIITA is regulated precisely in different cell types through 
cytokines or during particular stages of differentiation and influences therefore MHCII 
expression directly90,91. Peptides bound on class II molecules contain in general 13 to 18 
amino acid residues and have often internal conserved sequence motifs, but in contrast to 
MHCI peptides, conserved anchor residues are missing4. Antigenic peptides displayed in the 
groove of MHCII are recognized by CD4+ T-cells by interaction with the T-cell receptor 
(TCR). 
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T-cell subtypes 
Antigen recognition by naïve CD4+ T-cells leads, depending on the cytokines in the 
microenvironment, to activation, proliferation and differentiation in at least 4 types of effector 
T-cells (Th1, Th2, Th9, Th17). These Th-cell supopulations differ in their effector functions, 
based on the expression of transcription factors, cytokine production, chemokine responses 
and mobilization of other cell types (Fig. 5).  
 
Th1/Th2 
Th1-cells express the transcription factor Tbet, produce IFN-γ, TNF-β and Interleukin (IL) 2 
and mediate protection against intracellular pathogens, whereas Th2-cells express the 
transcription factor GATA-3, secrete cytokines like IL-4, IL-5, IL-9, IL-13, IL-25, IL-31, and IL-
33 and promote the elimination of parasitic helminth infections and are involved in allergic 
reactions92,93. GATA-3 inhibits the production of IFN-γ and increases the transactivation of 
the IL-4 promotor as well as the direct regulation of IL-5 and IL-13 expression. In contrast, 
Tbet develops IFN-γ production and simultaneously represses the Th2 cytokines IL-4 and IL-
594. Th1- and Th2-cell differentiation is induced by IL-12 and IL-4, respectively in vitro. 
However, many Th1-cell responses in vivo are partially or completely independent of IL-12, 
including those that cause diabetes in non-obese diabetic mice95 and those that are 
generated in response of soluble extract from Toxpoplasma gondii96 or viruses, such as 
lymphocytic choriomeningitis virus and mouse hepatitis virus97-99, suggesting that IL-12 
selects cells that are already committed to the Th1-cell lineage and enhances their effector 
function instead of Th1-cell differentiation induction100. Similar to Th1, Th2-cell responses in 
vivo are mostly independent of IL-4, following infection with helminths101. It has been argued 
that IL-4 might mainly function to amplify Th2-cell responses and might be necessary when 
other signals that drive Th2-cell differentiation are limiting100. The exact signals leading to T-
cell differentiation are unknown, but there is evidence which suggests that the Notch pathway 
can provide these signals100. Notch is a heterodimeric cell-surface receptor, expressed by 
CD4+ T-cells and involved in a broad range of differentiation and development processes102. 
In mammals two distinct families of Notch ligands are known, referred as Delta-like ligands 
(DLL) and the Jagged ligands. DLL proteins are induced through bacterial exposure 
(Acinetobacter lwofii and Lactococcus lactis) and exposure to TLRs ligands (LPS and CpG-
containing DNA) as well as infection with respiratory syncytial virus. Induction of Th1-cell 
differentiation by APCs correlates with the expression of DLL proteins, suggesting that the 
Notch pathway supports Th1-cell differentiation100. The inhibition of Notch pathway by γ-
secretase blocks IL-12-induced Th1-cell differentiation in vitro and in vivo103. However, 
experiments with Notch knockout mice have not confirmed if Notch alone is required for Th1-
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cell differentiation or if other proteins are also involved. Recent data from Fang et al104 have 
shown that specific blocking of Notch signalling in peripheral naïve CD4+ T-cells results in a 
loss of IL-4 production and integration of an activated Notch1 allele into naïve CD4+ T-cells 
leads to robust IL-4 induction, indicating that IL-4 production is regulated by Notch in a CD4+ 
T-cell-intrinsic manner. Furthermore, it has also been shown that Notch induces GATA3 
expression in a STAT6-independent manner, resulting in the stabilization of the Th2-cell 
phenotype100,104. GATA3 expression might be a key element that determines whether Notch 
induce Th1- or Th2 cell differentiation, but the molecular mechanisms that favour or prevent 
the expression of this crucial Th2-cell transcription factor are currently unclear104. 
As written above, Th1- and Th2-cells determine different biological functions and the 
progression of some diseases. The Th1-cell population is responsible for delayed-type 
hypersensitivity, production of IgG antibodies, excessive inflammation, autoimmune disease 
and tissue injury, whereas the Th2-cell subset activates eosinophils, supports 
immunglobulin-class switch to IgG1 and IgE and is involved in the development of airway 
inflammation, asthma and atopy.  
 
Th9/Th17 
The recent identification of the IL-17 and IL-9 producing T-helper (Th17 and Th9, 
respectively) cells has added complexity to the CD4+ effector T cell paradigm. Th17 cells are 
characterized by the production of IL-17, IL-17F and IL-22. IL-17 and IL-17F induce the 
production of proinfammatory cytokines, chemokines and metalloproteinases from various 
tissues and cell types, resulting in the recruitment of neutrophils to tissues105. Th17-cell 
differentiation and expansion does not require IL-17 in contrast to Th1- and Th2-cell 
differentiation, which is driven by their effector cytokines IFN-γ and IL4, respectively. Th17 
differentiation is instead induced by IL-6 and TGF-β106. In absence of IL-6, IL-21 produced by 
natural killer cells and natural killer T-cells, acts as an alternative inductor of Th17-cell 
differentiation107. The Th17 lineage-specific transcription factor is presumably STAT3 
because deletion of STAT3 prevents Th17 development108. In addition, the orphan nuclear 
receptor ROR-γt was also identified as lineage specific transcription factor for Th17 cells109. A 
Th17 response is induced by extracellular Gram-negative (Citrobacter rodentium, Klebsiella 
pneumoniae, Bacteroides spp. and Borrelia) and Gram-positive (Propionibacterium acnes) 
bacteria, as well as fungi such as Candida albicans. Furthermore, IL-17 and Th17-cells are 
also discussed to be potent inducers of autoimmunity through the promotion of tissue 
inflammation and the mobilization of the innate immune system, since increased IL-17 levels 
have been observed in patients with rheumatoid arthritis, multiple sclerosis, inflammatory 
bowel disease and psoriasis105.  
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In contrast to Th17-cells, still little is known about Th9 effector cells. They are distinct from 
other T-cell subtypes through production of IL-9. Interestingly, TGF-β, the cytokine involved 
in Th17 differentiation, was shown to “reprogram” Th2 cell differentiation in presence of IL-4, 
leading to Th9 cells, loosing their Th2 characteristics, including expression of GATA-3. 
Similar to Th2 immune response, IL-9 is important in the immune defense against helminth 
infections and also appears during allergic reactions in the lung110,111. It is not clear if such 
plasticity between closely related effector programs is the norm, allowing “fine-tuning” of the 
immune response and if a reversal from Th9 to Th2 cells could also occur111. 
 
Figure 5. Effector T-cell subsets. After antigen presentation by DCs, naive T-cells differentiate into TH1, TH2, TH9, and TH17 effector 
subsets. Their differentiation requires cytokines and other cofactors that are released from DCs and also expressed in the micromilieu. 
T-cell activation in the presence of IL-4 enhances differentiation and clonal expansion of TH2 cells, perpetuating the allergic response. 
IL-12, IL-18, and IL-27 induce TH1-cell differentiation; IL-4 and TGF-β induce TH9 differentiation; and IL-6, IL-21, IL-23, and TGF-β 
induce the differentiation of TH17-cells. Adapted from Akdis C., and Akdis M. J Allergy Clin Immunol (2009), 123. 735-46 
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CD4+CD25+ Treg cells 
5-10% of all CD4+ T-cells in the blood and other peripheral lymphoid tissues and more than 
20% in the bone marrow are CD4+CD25+ Treg cells. They express an α/β TCR repertoire 
with a high affinity for self-peptides112. For the development, maintenance and function of 
Treg cells the transcription factor forkhead box P3 (FOXP3) is required. Mice lacking FOXP3 
(known as scurfy mice) as well as individuals without functional FOXP3 develop a severe 
autoimmune-like lymphoproliferative disease, indicating that Treg cells are primary mediators 
of peripheral tolerance113. Although FOXP3 is an invaluable marker of mouse Treg cells, it 
has been controversially discussed, if additional co- or transcriptional factors beside FOXP3 
are also necessary in human Treg cell development and function, as a significant percentage 
of human activated T-cell express FOXP3 but do not possess regulatory activity113,114. 
Furthermore, in contrast to mouse Treg cells, induction of human Treg cells by stimulation 
with transforming growth factor (TGF) β does not confer a regulatory phenotype113. 
One suppression mechanism used by Treg cells is the secretion of inhibitory cytokines, such 
as IL-10 and TGF-β. IL-10 is known to be essential in peripheral tolerance to allergens, 
autoantigens, transplantation antigens, and tumor antigens and suppressive in T-cell 
proliferation and cytokine production93. Studies with allergy and asthma models have been 
shown that both naturally occurring and induced antigen-specific Treg cells control the 
disease depending on IL-10 and in some cases on IL-10 and TGF-β93,113,115. Additional 
suppression mechanisms by Treg cells are discussed113, e.g suppression by Treg cell-
mediated target-cell killing through secretion of granzyme A and perforin, following adhesion 
of CD18116 or suppression of DCs through direct interaction between DCs and Treg cells, in 
process involving the co-stimulatory molecule cytotoxic T-lymphocyte antigen 4 (CTLA4), 
which is constitutively expressed by Treg cells117,118. However, the importance of different 
mechanisms in different cellular functions is not appreciable so far113. 
 
B-lymphocytes 
Beside T-lymphocytes, B-lymphocytes are the second cell population involved in an adaptive 
immune response and are described briefly here. 
B-lymphocytes maturate in the bone marrow, circulate as naïve B-cell in the blood and lymph 
and are carried to spleen and lymph nodes. They are characterized by their synthesis and 
display of antigen specific antibodies, encoded by heavy and light immunoglobulin (Ig) 
genes. The recognition of antigen by membrane bound antibodies leads to a rapid cell 
division and differentiation into effector cells, called plasma and memory B-cells. Sites of 
intensive B-cell proliferation are called germinal centers and are surrounded by Th-cells 
activating the B-cells and migrated with them. Plasma cells secrete soluble antibody 
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molecules with specificity for antigen that is identical to the surface receptor of the parent B-
cell. Antibody molecules consist of two identical light polypeptide chains of about 22 kDa and 
two identical heavy chains of around 55 kDa or more. The antibody light chains are encoded 
by a variable (V), joining (J) and constant (C) gene segment whereas the heavy chain gene 
contains a V, D (diversity), J, and C gene segment. In mice and humans antibody diversity is 
generated by multiple germ-line gene segments, combinatorial V-(D)-J joining, junctional 
flexibility, P-region nucleotide addition, N-region nucleotide addition, somatic hypermutation 
and combinatorial association of light and heavy chains. Heavy chains consist of five 
different constant regions (µ, δ, γ, ε and α), which determine the antibody class (IgM (µ), IgG 
(γ), IgA (α), IgD (δ), or IgE (ε)) and effector function4. IgE are associated with allergic 
disorders and the features of allergic inflammation are described in more detail subsequently.  
 
IgE driven immune responses and the development of allergies 
To mount an IgE mediated immune response, first antigen presenting cells (e.g. dendritic 
cells) have to differentiate and to promote the formation of allergen-specific Th2-cells, a 
process that may be enhanced by engagement of Notch at the surface of T-cells with the 
Notch ligand Jagged on dendritic cells. Th2-cells subsequently stimulate B-cell to IgE class 
switch by secretion of IL-4 and IL-13 and by ligation of suitable co-stimulatory molecules 
Figure 6. Sensitization to allergens in the airway. DCs become activated after allergen uptake and migrate to regional lymph nodes 
or to sites in the local mucosa, where they present allergen peptides on MHCII molecules to naïve T-cells. In the presence of IL-4, 
naïve T-cells acquire the characteristics of TH2-cells, a process that may be enhanced by engagement of Notch at the surface of T-
cells with Jagged on DCs. TH2-cells produce IL-4 and IL-13. In the presence of these cytokines and the ligation of suitable co-
stimulatory molecules (CD40 with CD40 ligand, and CD80 or CD86 with CD28), B-cells undergo Ig-class-switch recombination, and 
IgE antibodies are produced. Basophils and mast cells also can produce IL-4 and/or IL-13, and can stimulate B-cells through CD40 
(not shown). IgE diffuses locally and enters the lymphatic vessels. It subsequently enters the blood and is then distributed 
systemically. After gaining access to the interstitial fluid, allergen-specific or non-specific IgE binds to the high-affinity receptor for 
IgE (FcRI) on tissue-resident mast cells, thereby sensitizing them to respond when the host is later re-exposed to the allergen. 
Adapted from Galli SJ, et al. Nature 2008; 454(7203):445-54. 
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(CD40 with CD40 ligand, and CD80 or CD86 with CD28) and recruit eosinophils through 
releasing of IL-5, IL-9, and granulocyte/macrophage-colony stimulating factor (GM-CSF). B-
cells are also stimulated by IL-4 and/or IL-13 producing basophils and mast cells through 
CD40119. Allergen-specific or unspecific IgE diffuses locally, enters the lymphatic system and 
the blood and is distributed systemically. It binds to the high-affinity receptor for IgE (FcεRI) 
on mast cells, thereby sensitizing them (Fig. 6). Sensitization does not produce symptoms 
(for example, if sensitization occurs by way of the airways, bronchoconstriction does not 
occur). However, a later re-exposure to the same allergen induces cross-linking of receptor-
bound IgE with subsequent mast cell degranulation and the release of proinflammatory 
molecules such as histamines. Such an acute reaction is known as early-phase reaction or a 
type I immediate hypersensitivity reaction and causes vasodilation, increased vascular 
permeability with oedema, and acute functional changes in affected organs. During the 
course of the reaction often mediators are released to promote the local recruitment and 
activation of leukocytes, leading to late-phase reactions4,119,120. Late-phase reactions typically 
occur 2-6 h after allergen exposure and often peak after 6-9 h. The reaction is characterized 
by infiltration of cells of the innate and adaptive immune system (neutrophils, eosinophils, 
macrophages, Th2-cells, and basophils) and persistent mediator production by resident cells, 
such as mast cells4,119. 
 
Allergic diseases and the “Hygiene Hypothesis” 
Over the past two to three decades the prevalences of allergic diseases (also known as 
atopic diseases) including allergic rhinitis (also referred as hay fever), atopic dermatitis (also 
known as eczema), allergic (or atopic) asthma and some food allergies has been significantly 
increased in the western world119-122. Currently, more than 130 million people suffer from 
asthma. Furthermore, in the wake of improved hygiene and socio-economic conditions as 
well as antibiotics and vaccinations, the incidence of many infectious diseases has 
decreased. In contrast, the prevalence of allergic diseases is considerably lower in 
developing countries121,122.  
The hygiene hypothesis states that a lack of infections and unhygienic contact early in 
childhood increases the risk of developing allergic diseases and was first proposed by 
Strachan in 1989. He observed that the prevalences of hay fever and eczema was inversely 
related to the number of siblings in a family suggesting that unhygienic contact to older 
siblings transmit infection in early childhood, which leads to protection against allergic 
disease123. It has been suggested that the limited exposure to bacterial and viral organisms 
during early childhood results in a shift to Th2-cell expansion through insufficient stimulation 
of Th1-cells. In fact many epidemiological studies have shown that children growing up on a 
farming environment rich in bacterial endotoxin (e.g. the TLR4 ligand LPS) or living an 
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anthroposophic lifestyle are more protected in developing hay fever and atopic 
sensitization124-127. Environmental factors correlate with the gene expression of CD14, TLR2 
and TLR4128,129, and were related to different farm animal species the mother has contact 
with during pregnancy in a dose-dependent manner128. Additionally, children with contact to 
farm animals, consumption of farm milk or haying, have a significantly higher expression of 
different TLRs and CD14130. The manifestation of childhood asthma and allergies occurs in 
the first years of life 131. Therefore pre- and early postnatal exposure seems to determine the 
development of childhood asthma and allergies131. In chapter A1 we investigated the 
influence of farming exposures during pregnancy and in the first year of life on the 
expression of different TLRs and CD14. 
 
Allergic diseases and genetic associations 
The innate immune system is an important mediator between microbial exposure and 
regulation of cytokine response and subsequent development of asthma and allergy. 
Different TLR polymorphisms are identified, which seem to be involved in pathogenesis of 
asthma. Results of the ALEX (ALlergy and EndotoXin) study have shown that farmer′s 
children carrying one or two TLR2 – 16934T alleles had significantly reduced prevalences of 
asthma, fewer current asthma symptoms, less hayfever and atopy132. The TLR2/+596C 
polymorphism was found to be associated with an increased risk for asthma133. For a TLR4 
genetic variant (TLR4/+4434) a gene-environment interaction was found, since only farmer′s 
children heavily exposed to endotoxin showed reduced atopy, whereas this effect was 
reversed in low endotoxin exposure132. Polymorphisms of TLR1 (TLR1/-2192 C/T; TLR1/743 
A/G) TLR6 (TLR6/-2078 T/A) and TLR10 (TLR10/2323 A/G) were shown to be highly 
significant, inversely associated with atopic asthma in a case-control study134. The CD14/-
260T allele is described to protect against asthma and asthma severity in family-based and 
case-control studies135. The well-studied CD14/-260C allele has been shown to be negatively 
associated with asthma in skin prick test positive subjects133 and children with regular contact 
with pets have higher levels of both total and specific serum IgE to aeroallergens, whereas 
children with regular contact to stable animals have an opposite association136, indicating that 
the type and concentration of microbial molecules to which children are exposed may 
influence the genetic associations observed. Behind them, differences in timing of exposure 
might be one explanation for different results between studies135. We investigated in chapter 
A2 which factors, polymorphisms or a genotype-prenatal farm environment interaction, could 
influence the TLRs gene expression and investigated whether the TLRs and CD14 gene 
expression in cord blood samples is associated with the development of atopic dermatitis in 
the first 2 years of life.  
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Studying the protective factors against childhood allergies: The ALEX-, Parsifal-, and 
PASTURE Study 
In the past, different epidemiological studies aimed to identify not only risk but also possible 
protective factors against allergic diseases. Results of two European cross-sectional studies 
were meaningful: The ALEX (Allergy and EndotoXin) study, which investigated the 
environmental exposure to endotoxin during pregnancy and first year of life and its relation to 
allergic diseases137 as well as the PARSIFAL (Prevention of Allergy Risk factors for 
Sensitization in children related to Farming and Anthroposophic Lifestyle) study which 
compared children from farm or anthroprosophic families with appropriate reference children 
from Austria, Germany, Netherlands, Sweden and Switzerland138. However, both studies 
assessed the early exposure retrospectively. To investigate the temporal sequence of 
events, relating early life exposures to the maturation of the immune response and the 
development of tolerance and allergies, respectively, the PASTURE (Protection against 
Allergy – Study in Rural Environment) study was developed. This prospective birth cohort 
study located in rural areas in five European countries (Germany, Austria, Switzerland, 
France and Finland) has the overall aim to assess the role of indoor exposure to various 
microbial products for the development of childhood asthma and allergies and to investigate 
the immunological and genetical mechanisms which are involved in the determination of 
individual responses to these environmental influences139. Our investigations, described in 
chapters A1-A3, are based on the PASTURE study.  
 
Food allergy: cause and treatment 
Immediately after birth, the mucous membrane of the gastrointestinal tract is colonized by a 
large variety of microorganisms and environmental antigens. There are numerous 
mechanisms to protect the body from invasion by potentially pathogenic microorganisms: 
Behind the physical barrier, the production of secretory IgA seems to be particularly 
important. Specialized epithelial cells, so called M cells, but also enterocytes, or dendritic 
cells take up dietary proteins in the gut and presented them as fragment to naïve T-cells in 
the gut-associated lymphoid tissue (GALT)4. Healthy individuals exhibit a transient 
proliferative response to food antigens, but non-responsive (oral tolerance), whereas atopic 
individuals develop an exaggerated Th2 response to specific dietary antigens140. Up to 6% of 
children under 4 years of age and 3-4% of adults in westernized countries suffer from clinical 
symptoms of food allergy and their prevalence appears to be rising141. Many of them have 
IgE-mediated food allergy that may lead to a fatal outcome or to life-threatening conditions 
such as anaphylactic shocks (49% of life-threatening cases), systemic reactions (33%), 
laryngeal angiodedema (13%) or acute asthma (5%)142. The cause of food allergy is still 
unclear. There is evidence that food allergy is at least in part genetically determined. Peanut 
 23 
allergy, for example, is about tenfold more likely to occur in a child with a parent or sibling 
who is peanut allergic compared to the general population risk143; An IL10 gene 
polymorphism has been found to be associated with food allergy in a Japanese population144 
and an IL13 gene polymorphism has been associated in German children145. There are many 
epidemiological studies examining the prevention of allergic diseases, however little work 
has been done with respect to the hygiene hypothesis and food allergy. Recently, 
experimental findings of in vivo studies have shown that neonatal mucosa exposure to 
Staphyloccocus aureus reduces the risk of developing food allergy146.  
The current treatment of food allergic diseases is to avoid trigger foods and to treat allergic 
reactions. Different therapies are being evaluated to treat or prevent food allergies: Attempts 
of subcutaneously delivered native peanut allergen resulted in modest clinical improvements 
and significant adverse anaphylactic effects147. Further therapies are in clinical or preclinical 
studies including peptide vaccination, plasmid-DNA encoded vaccines, modified protein 
vaccine, anti-IgE or cytokine/anticytokine treatment143. We observed some promising results 
in murine in vivo studies with the use of attenuated, intracellularly living bacteria which 
deliver allergen in small concentration (chapter B1 and B2). 
  
Aims and objective 
Results of retrospective analysis provided first evidence that stimulation with farming factors 
during pregnancy and early in life affects the innate immunity and development of allergic 
diseases. In Chapter A1 we investigated the influence of farming exposures during 
pregnancy and in the first year of age on the expression of TLRs and CD14 as important 
receptors of the innate immunity, at time of birth and at the age of one. The analysis was 
carried out with samples of farming and non farming families living in rural environments 
across five European countries within the prospective longitudinal birth cohort study 
PASTURE  
The hygiene hypothesis has proposed that insufficient stimulation of the immune system may 
influence the development of allergies. In Chapter A2 we analyzed the association of TLRs 
and CD14 gene expression at time of birth and the development of atopic dermatitis in the 
two first years of life. Furthermore, we investigated, if the TLRs/CD14 gene expression could 
be influenced by genetic factors (single nucleotide polymorphisms) or by a gene-environment 
interaction.  
Recent studies indicate that prenatal, but not postnatal, vitamin D intake protects from the 
development of wheeze and atopic diseases in 3 and 5 years old children. Vitamin D, has a 
immunmodulatory capability and is able to induce tolerogenic dendritic cells (DCs). These 
cells are characterized to upregulate two inhibitory receptors immunglobulin-like transcripts 
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(ILT)3 and ILT4, which inhibit nuclear factor (NF)-κB activation and the subsequent 
inflammatory responses. In addition, tolerogenic DCs are able to induce regulatory T cells 
(Treg), render naïve T cells anergic, and are therefore interesting candidates in the 
development of atopic diseases. To evaluate, if prenatal vitamin D supplementation could 
induce tolerogenic DCs at birth, we analyzed in Chapter A3 the gene expression levels of 
ILT3 and ILT4 in cord blood samples of the PASTURE population.  
 
The increased incidence of food allergy in developed countries is in particular serious, 
because of missing therapeutic and preventive strategies beside the avoidance of triggering 
foods. We aimed to develop an allergen-specific immune therapy, where patients are treated 
with increasing concentrations of the allergen and which is already established against hay 
fever or insect sting allergies. As a tool to release the allergen in small concentration we 
used intracellular living attenuated bacteria (Salmonella enterica serovar Typhimurium). First, 
we studied the allergen expression in different attenuated Salmonella strains and 
investigated in a preliminary in vivo mouse model the influence of pre-treatment with such 
bacteria on the development of allergic symptoms (Chapter B1). Next, we tested, in two 
murine sensitization studies intensively the effect of combined intake of microorganisms and 
the release of low allergen amounts in a preventive as well as in a therapeutical approach 
(Chapter B2).   
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Abstract 
Background  
Decreased microbial exposure may be one reason for increased incidence of allergic 
disorders in westernized countries.  
Objective  
We investigated the influence of prenatal and early postnatal farming exposures on the 
expression of innate immune receptors (Toll-like receptors and CD14) at time of birth and at 
one year of age. 
Methods  
The prospective birth cohort study (PASTURE) comprises 530 children of farming and 603 
children of non-farming families, and their mothers from rural areas of 5 European countries 
(Austria, Finland, France, Germany and Switzerland). Gene expression of Toll-like receptors 
(TLRs) and CD14 were analyzed at time of birth and at one year of age. Mothers answered 
questionnaires about health issues, farming exposure and potential confounders such as 
active and passive smoking, parental education and family size within the third trimester of 
pregnancy as well as two and twelve month after birth. 
Results 
The expression of TLR7 and 8 were significantly higher in farmer children compared to non 
farmer children at time of birth. The same trend was observed for TLR 1, 2, 4, 5, 6, and 9.  
At one year of age TLR5 and 6 were significantly higher expressed in children, who 
consumed farm milk during the first year of age. Consumption of unboiled farm milk was 
positively associated with CD14 and TLR4, 5, 6, and 7.  
Consumption of unboiled farm milk compared to consumption of no farm milk showed a 
positive association with all tested differences of TLR expression (diff-TLR) between time of 
birth and one year of age and a significant result was observed for diff-TLR6. If the first 
unboiled farm milk intake occurs in the first 10 months a significant effect was observed for 
diff-TLR6 and 7 and a nearly significant effect for diff-TLR1 and 4 but not if the first intake 
occurs between 10 and 12 month of life.  
Conclusion 
Working on a farm during pregnancy influences the expression of different TLRs and CD14 
in cord blood. Farm milk, especially unboiled farm milk consumption during the first 12 
months of life is associated with TLRs expression at one year of age. It seems that both the 
pre- and early postnatal farming exposures influence the expression of TLRs in children.  
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Introduction 
The prevalence of allergic diseases has increased and stabilized on a high level in wealthy 
countries in recent decades1-6. These observations may be based on decreased exposures 
to endotoxin caused by modern public health practices, suggesting that microbes or 
microbial components are important stimuli for immune education and protection against 
allergic diseases.  
Immune responses to microorganisms are mediated by receptors of the innate immunity 
such as Toll-like receptors (TLRs) and CD14. TLRs are highly conserved, germ-line encoded 
receptors located on the cell surface or intracellularly on endosomal membranes of different 
immune, but also epithelial and endothelial cells and recognize conserved microbial 
structures7. The farming environment was shown to be rich of different bacterial components 
like lipopolysaccharid (LPS) or N-acetyl-muramic acid8,9 both ligands, which are recognized 
by TLRs and CD14. A direct influence of farming exposition on the expression of TLR2 and 
CD14 was found to be increased in children living on a farm compared to non-farmer 
children10. Children with contact to farm animals, consumption of farm milk or haying, have a 
significantly higher expression of different TLRs and CD1411. Furthermore, maternal 
exposure to different farm animals during pregnancy increased the expression of TLR2, 
TLR4 and CD1412, indicating that the development of the infantile innate immune system is 
affected through the maternal farming exposition. However, these results are based on 
retrospective epidemiological studies with school-aged children. To maintain further insights 
in the importance of early prenatal and postnatal farming stimulation and the consequence 
on the development of allergic diseases, the prospective longitudinal birth cohort study 
PASTURE (Protection against allergy: study in rural environment) was established which 
includes farming and non farming families living in rural environments.  
The aim of the present study was to investigate the influence of farming exposures during 
pregnancy and in the first year of age on the expression of TLRs and CD14 at time of birth 
and at the age of one. 
 
Methods 
Population and study area 
PASTURE is a prospective birth cohort study located in rural areas in five European 
countries: Austria, Finland, France, Germany and Switzerland. This present analysis utilizes 
data of altogether 1133 children, 530 children of farming and 603 children of non farming 
families, and their mothers. 
Potential participating families were contacted in the third trimester of pregnancy13. Exclusion 
criteria were living on a farm without livestock, maternal age below 18 years, premature 
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delivery, genetic disease in the offspring, absent telephone connection and insufficient 
knowledge of the country’s language. Women living on a farm where livestock was held or 
who or whose partners actively run a farm were considered farming women. As controls a 
subset of the population living in close neighborhood in likewise rural environment not 
occupationally involved in farming activities was assigned. 
Questionnaires 
Within the PASTURE study group an extensive questionnaire was developed using 
questions from the International Study of Allergy and Asthma in Childhood (ISAAC)14, the 
Allergy and Endotoxine (ALEX) study15 the PARSIFAL (Prevention of Allergy-Risk factors for 
Sensitization in children related to farming and anthroposophic lifestyle) study16, as well as 
questions derived from the American Thoracic Society (ATS) questionnaire17 for the 
assessment of respiratory health in the parents. The questionnaires were administered by 
interview to the mother of the child within the third trimester of pregnancy and two and twelve 
month after birth of the study child. Questions were designed to assess respiratory and other 
health issues of the mother as well as a range of agricultural exposure. In addition, questions 
about potential confounders such as active and passive smoking, parental education and 
family size were included in the questionnaires. 
Expression of Toll-like receptors and CD14 
Cord blood was taken by the midwives with PaxGene tubes shortly after cord clamping. 
Blood samples at year one were taken during a field visit from the basilic or hand vein. The 
blood was frozen at minus 80°C within twenty-seven hours after delivery at the local 
laboratory. At a central laboratory total mRNA was isolated with the PaxGene Blood RNA Kit 
(Qiagen, Hilden, Germany) supplemented with RNase-free DNase (Qiagen) and stored at 
minus 80°C. For reverse transcription (RT), 600ng of total RNA in a final volume of 60µl were 
used and adequate amounts of TaqMan® Reverse Transcription Reagents (Applied 
Biosystems, Foster City, USA) were added. The running conditions were as follows: 10 min 
25°C; 40 min 42°C; 5 min 95°C. The gene quantification was performed on an ABI Prism 
7900 Sequence Detection System (Applied Biosystems) using the TaqMan® low density 
array (LDA) system of Applied Biosystems with the following running conditions: 45x (2 min 
50°C; 10 min 95°C; 15 sec 95°C; 1 min 60°C). The used predeveloped primer/probes 
(Applied Biosystems) are listed in Table 1. The determined gene expression values were 
normalized to the parallel measured endogenous controls 18S rRNA and beta-2-
microglobulin. The data was analyzed using the comparative Ct method according to the 
manufacturer’s instructions (Applied Biosystem).  
 
 
 40 
Table 1: Primer/probe assay 
Assay ID Gene 
Hs00413978_m1 TLR1 
Hs00610101_m1 TLR2 
Hs00152933_m1 TLR3 
Hs00370853_m1 TLR4 
Hs00152825_m1 TLR5 
Hs00271977_s1 TLR6 
Hs00152971_m1 TLR7 
Hs00607866_mH TLR8 
Hs00370913_s1 TLR9 
Hs00169122_g1 CD14 
Hs99999907_m1 β2 microglobulin 
Hs99999901_s1 18S rRNA 
 
Statistical analyses 
Frequencies of the characteristics of the pregnant women and the children were compared 
according to farming classification by Chi2-test. 
To quantify the results obtained by real-time RT-PCR for CD14 and TLR1, 2, 4, 5, 6, 7, 8. 9, 
the comparative threshold method, described by Giulietti and colleagues, was used18. We 
choose a non farmer child with results above detection limit for all mRNA-measurements in 
cord blood and at year one as a reference. The results give a multiple of amount of mRNA in 
comparison to the reference. Because the distribution of the transformed gene expression 
levels was skewed, the calculated variables were log-transformed (natural logarithm), 
resulting in a good approximation to normal distribution.  
The transformed data were used in linear regression to calculate associations between 
mRNA expressions and farming or other exposures. To assess the development of mRNA 
expressions from birth to year one, the difference of normalized mRNA expressions from 
cord blood and year one was used (diff-mRNA). Mean ratio (mr) and p-values are given. P-
values <0.05 were considered significant. 
Associations between mRNA expressions and exposures were calculated in bivariate 
regression models. 
An overall association of farming status on mRNA expressions in cord blood and farm milk 
consumption on the set of mRNA expressions at year 1 or diff-mRNA respectively was tested 
using multivariate analyses of variance (manova). Given the values for Wilks’ lambda and the 
level of significance outcome models for singular mRNA expressions were accordingly 
classified and interpreted. 
All of the statistical analysis was performed using STATA 10. 
Quality control 
Extensive quality control measures have been incorporated in the PASTURE cohort study 
particularly for laboratory work but also for field work. 
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Ethical approval  
The study was approved by the ethical boards of the five study centers, and written informed 
consent was obtained from the children’s parents for questionnaires, blood samples and 
genetic analyses. 
  
Results 
Of 2871 women with response after contacted for the PASTURE study 1772 (62%) were 
identified as eligible (Fig 1). 64% of these women were willing to participate and included in 
the study (530 farming and 603 non farming women). For mRNA analyses 938 (52.5% non 
farming, 47.5% farming children) cord blood samples (82.3% of study population) and 773 
(51% non farming, 49% farming children) blood samples of year one (68.3% of study 
population) were available. Table 2 shows environmental and farming characteristics of 
pregnant women and children in first year of life. 
The study-population and the populations with available mRNA measurements at birth and 
year one did not differ in respect to farming status (data not shown). Compared to the study 
population a higher percentage of Finnish and French blood samples were available. No 
differences were seen with respect to age of pregnant mothers, her educational level, 
number of older siblings, smoking status of the mother, pet owner ship, family history of 
asthma, hay fever and eczema or the prevalence of farm milk consumption. 
Number of pregnant women who responded
to first inquiry: 2871
Eligible: 1772 (62 %) 
Selected** : 1133 (64 %)
thereof
non farmer: 603 (53.2 %) farmer: 530 (46.8 %)
Inclusion criteria* not fulfilled or missing data: 1099
Year 1 questionaire filled in: 1036 (91.4 %**)
thereof
non farmer: 545 (52.6 %) farmer: 491 (47.4 %)
Not willing to participate: 639
Cord blood for mRNA analyses: 938 (82.3 %**)
thereof
non farmer: 492 (52.5 %) farmer: 446 (47.5 %)
Blood year 1 for mRNA analyses: 773 (68.3 %**)
thereof
non farmer: 394 (51 %) farmer: 379 (49 %)
Missing cord blood: 195
thereof
non farmer: 111     farmer: 84
Missing blood year 1**: 360
thereof
non farmer: 209 farmer: 151
Figure 1. Selection of PASTURE study population and participants for mRNA analyses 
* Inclusion criteria were: living on a farm with livestock, maternal age above 18 years, term delivery, no genetic 
disease in the offspring, telephone connection, and sufficient knowledge of the country’s language.  
**selected: pregnancy questionnaire filled in. 
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Heterogeneity of TLR expression between centers 
Comparison of centers revealed heterogeneity of mRNA expression between centers 
depending on farming status. Particularly Switzerland (CD14, TLR7 and 9) and Finland 
(TLR1, 2, 4, 5, 6 and 8) had an inverse effect of farming status on mRNA expressions in cord 
blood. Deeper exploration of differences between centers did not show any farming activity 
responsible for the contrary effects but an interaction for farming status between the Finish 
and Non-Finnish population.  
 
Farmer Non Farmer Chi2
spalte1 N % N % p-value
population at birth 530 46.8 603 53.2
       population at year1 (percent of population at birth) 491 92.6 545 90.4
       male 266 50.2 293 48.6 0.966
center
       Austria 105 47.7 115 52.3
       Switzerland 107 44.2 135 55.8
       France 94 46.3 109 53.7 0.389
       Germany 112 44.1 142 55.9
       Finland 112 52.3 102 47.7
specific farming exposure of child
       in utero through maternal exposure
       regular stay in stable: yes 462 87.2 107 17.7 <0.001
       regular stay in barn: yes 360 67.9 65 10.8 <0.001
       maternal farm milk consumption: yes 406 76.6 98 16.3 <0.001
               only boiled fmilk 17.7 4.5 <0.001
               any unboiled fmilk 58.5 11.6 <0.001
       contact to >= 2 animal species 196 37.0 61 10.1 <0.001
       during year1*
       child lived/or parents worked on farm: yes 484 98.6 10 1.8 <0.001
       regular contact to farm: yes 485 98.8 78 14.3 <0.001
       regular contact to stable: yes 331 67.4 41 7.5 <0.001
       farm milk consumption: yes 280 57.0 56 10.3 <0.001
               only boiled farm milk 28.3 5.0 <0.001
               any unboiled farm milk 28.3 4.4 <0.001
                       unboiled farm milk before month 1-9 11.8 1.5 <0.001
                       first unboiled farm milk month 10-12 15.9 2.8 <0.001
general exposures of child
       maternal history of asthma: yes 38 7.2 61 10.1 0.08
       maternal history of hay fever: yes 108 20.4 196 32.5 <0.001
       paternal history of asthma: yes 28 5.3 43 7.1 0.15
       paternal history of hay fever: yes 83 15.7 188 31.2 <0.001
       >= 2 older siblings 255 48.1 124 20.6 <0.001
       maternal smoking during pregnancy: yes 46 8.7 112 18.6 <0.001
       maternal smoking while breast feeding*: yes 17 38 3.2 38 6.3 0.01
       cat and/or dog in pregnancy: yes 430 81.1 233 38.6 <0.001
       cat and/or dog during year1*: yes 402 75.8 191 31.7 <0.001
       at least 4 month breast feeding*: yes 301 56.8 334 55.4 0.962
8
15
58
78
27
70
27
24
139
139
94
310
Table 2. Environmental and farming characteristics of pregnant women and children in first year of life, by 
farming status. 
*percent of population at year 1. 
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Associations of farming status and TLR/CD14 expressions at birth 
The expression of TLR7 and 8 were significantly higher in cord blood of farmer compared to 
non farmer children (Fig. 2). The same but not significant trend was observed for TLR 1, 2, 4, 
5, 6, and 9.  
 
Association of maternal exposure on Toll-like receptors and CD14 at birth 
Maternal smoking during pregnancy led to decreased expression of TLRs, especially TLR6 
and 8, which were reduced significantly. Other exposures during pregnancy (regular stay in 
stable, farm milk consumption, contact to less or more than two animal species, older 
siblings) did not reveal significant associations for more than one mRNA expression at birth 
(data not shown). 
Association of farm milk consumption at year 1 and expression of Toll-like receptors and 
CD14 at one year of age 
Children who consumed farm milk during the first year of age have significantly higher 
expression of TLR5 and 6. Consumption of unboiled farm milk was positively associated with 
CD14 and TLR4, 5, 6, and 7 (Table 3). Other positive associations were observed when 
0
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Figure 2. Association of farming/non farming status and mRNA-expressions (normalized to 
18s/b2m) at birth, adjusted for maternal history of asthma and hay fever, sex, maternal smoking in 
pregnancy, and center. Shown are mean ratios, whiskers represent the 95% confidence intervals. 
Wilks’ lambda F(1,1)= 1.90 and p-value=0.048.  
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older siblings were existent (significant for CD14, TLR4, 6) or mother smoked during lactation 
(CD14, TLR4). Farming status or regular contact to farm was not associated with mRNA 
expressions at year one (data not shown).  
Farm milk consumption during first year of life and differences of TLR expression between 
cord blood and one year of age (diff-mRNA) 
Consumption of unboiled farm milk compared to consumption of no farm milk showed a 
positive association with all tested diff-mRNA with a significant result for diff-TLR6. When the 
first intake of unboiled farm milk was taken in the first 10 month a significant effect was 
observed for diff-TLR6 and 7 and a nearly significant effect for diff-TLR1 and 4. These results 
disappeared if the first intake occurs between 10 and 12 month of life (Table 4).  
 cd14_ 1  tlr1_1  tlr2_1  tlr4_1  tlr5_1  tlr6_1  tlr7_1  tlr8_1  tlr9_1  
 m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value 
farm milk 
consumption: 
yes/no  
1.07  0.14 8  1.04  0.47 2  1.04  0.42 1  1.08  0.18 1  1.11  0.05 0  1.10  0.04 2  1.10  0.13 2  1.04  0.54 6  1.10  0.12 8  
only boiled 
farm milk vs 
no farm mil k  
0.98  0.79 8  0.95  0.45 1  1 . 0  0.99 0  0.92  0.28 6  1.04  0.62 0  0.99  0.83 1  0.97  0.74 5  0.93  0.37 1  1.05  0.54 4  
any unboiled 
farm milk vs 
no farm mil k  
1.15  0.02 5  1.13  0.80  1.06  0.29 9  1.26  0.00 2  1.18  0.01 7  1.23  0.00 1  1.25  0.00 7  1.15  0.07 4  1.17  0.06 6  
 Table 3. Associations* of exposure during year 1 and mRNA-expression** at year 1 
*Linear Regression: bivariate model; ** normalized for 18s/b2m,; mr=mean ratio. 
Wilks’ lambda F(1,1)=2.1, p-value=0.073 (results of multivariate analysis of variance (manova) of mRNA expression and 
farm milk consumption (unboiled farm milk/no or only boiled farm milk) adjusted for center). 
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 diff cd1 4  diff tlr1  diff tlr2  diff tlr4  diff tlr5  diff tlr6  diff tlr7  diff tlr8  diff tlr9  
 m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value m r  p-value 
farm milk 
consumption: 
yes/no  
1.13  0.32 0  1.08  0.52 5  1.03  0.79 3  0.99  0.96 9  0.92  0.48 3  1.17  0.20 3  0.99  0.95 4  0.97  0.82 7  1.04  0.81 9  
only boiled farm 
milk vs no farm 
milk 
1.10  0.55 4  0.90  0.48 3  0.97  0.84 7  0.78  0.14 3  0.83  0.24 0  0.92  0.58 6  0.78  0.23 6  0.89  0.42 4  0.98  0.92 2  
any unboiled 
farm milk vs no 
farm milk 
1.14  0.39 5  1.21  0.19 6  1.05  0.71 2  1.19  0.29 0  0.95  0.74 1  1.41  0.02 3  1.19  0.40 1  1.00  0.98 2  1.05  0.78 4  
                   
unboiled farm 
milk vs no/only 
boiled farm milk  
1.11  0.49 4  1.26  0.09 8  1.06  0.63 8  1.31  0.09 0  1.18  1.01  1.46  0.00 8  1.30  0.17 5  1.05  0.74 0  1.06  0.74 0  
first unboiled 
farm milk before 
month 10  
1.05  0.82 5  1.39  0.09 8  1.26  0.20 1  1.44  0.10 4  1.21  0.37 2  1.64  0.01 6  1.92  0.02 0  1.23  0.30 5  1.11  0.68 8  
first unboiled 
farm milk month 
10-1 2  
1.14  0.46 0  1.21  0.26 3  0.95  0.75 6  1.24  0.26 0  0.91  0.60 9  1.38  0.06 6  1.03  0.89 7  0.96  0.79 2  1.03  0.87 8  
 
Table 4. Associations* of farm milk consumption in the first year of life and difference of mRNA expression** (diff-
RNA) between cord blood and year 1.  
* Linear regression adjusted for being a farm child, maternal history of asthma, maternal history of hay fever, sex, 
number of older siblings, and center; **normalized for 18s/b2m;  mr=mean ratio. 
Wilks’ lambda F(1,1)= 2.8, p-value=0.003 (results of multivariate analysis of variance (manova) of difference of 
mRNA expression and farm milk consumption (unboiled farm milk/no or only boiled farm milk) adjusted for  
maternal history of asthma, maternal history of hay fever, sex, and center) 
 
 
Discussion 
In contrast to previous retrospective epidemiological analysis, we were able to demonstrate 
in a prospective approach that the expression of different Toll-like receptors (TLRs) and 
CD14 in cord blood of children whose mothers worked on a farm during pregnancy were 
partly significantly higher compared to non farming newborns. Furthermore, the TLRs 
expression at one year of age was associated with farm milk consumption, especially 
unboiled farm milk. This indicates that both the pre- and early postnatal farming exposure 
influence the expression of TLRs in children. In fact, numerous epidemiological studies have 
shown that growing up on a farm protects against the development of hay fever and atopic 
sensitization in childhood and adulthood15,19-24. Consumption of unpasteurized farm 
milk12,15,25, exposition to animal stables15,23 and contact to different farm animal species12 
mainly during pregnancy or early in life have been identified as important beneficial factors 
against allergic diseases.  
TLRs as receptors of innate immunity are an important link between environmental exposure 
and initiation of subsequent adaptive immune responses26,27. Stimulation of TLR2 and TLR4 
in a murine allergy model resulted in a decrease of allergic inflammatory response, mainly if 
the stimulation occurs before sensitization28. Further data of the Pasture study have shown 
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that children with atopic dermatitis in the first two years of life have a significant decreased 
expression of TLR5 and 9 in cord blood. These differences are not based on genetic 
modifications but on gene-environment interaction since the farming status increases 
significantly the expression of both genes among children with a genetic predisposition 
(unpublished data, chapter A2). These results indicate that the innate immunity is at least in 
part an important mediator for protection against allergic diseases.  
However, two important points have to be resolved: First, since we did not find a single 
exposition factor, it still remains to clarify which combinations of exposures are relevant to 
influence TLR expression effectively and second, how TLRs stimulated by farming factors 
can modulate the subsequent immune cascade. The earlier proposed concept that 
insufficient immune stimulation disturbs Th1/Th2 balance in allergic diseases, appears 
deficient to explain many experimental and clinical observations, where both T-cell subtypes 
are involved29-31. In the last decade the scientific interest on T regulatory cells (Tregs) and 
their function to balance immune responses and maintaining peripheral tolerance has risen. 
Children who outgrew their cow`s milk allergy were found to have higher circulating CD4+ 
CD25+ Treg cells compared to children who maintained clinically active allergy32. It was 
shown that the expression of the important Treg cell marker transcription factor forkhead box 
protein P3 (FOXP3) negatively correlates with IgE, eosinophilia, and IFN-γ levels, and 
patients with asthma and atopic dermatitis have had a significant lower FOXP3+/CD4+ ratio 
compared to healthy individuals33. Furthermore, it was found that the influence of prenatal 
farm exposures results in an increased number of Treg cells in cord blood and reduced Th-2 
cytokine production and the number of animal species increased FOXP3 expression34. 
How prenatal farm exposure and the exposition to farm milk early in life influence the 
expression of innate immune receptors and further modulate adaptive immune responses, 
especially the promotion of Treg cells, requires further work. 
 
Contribution to this work 
The PASTURE project was planned and is coordinated by E. von Mutius et al.13. RNA-
isolation, reverse transcription and gene expression measurements were done by myself at 
the Children's Hospital Zürich. Statistical analyses were performed by Sondhja Bitter and 
Letizia Grize at the Institute of Social and Preventive Medicine (University of Basel). The 
manuscript was written by myself.  
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Abstract 
Background  
Based on the hygiene hypothesis, it has been suggested that an insufficient stimulation of 
the immune system might contribute to the development of allergic diseases. Epidemiological 
evidence supporting the association with atopic dermatitis remains inconsistent.  
Objective  
We studied whether the gene expression of innate immunity receptors (Toll-like receptors, 
TLRs) in cord blood samples is associated with the development of atopic dermatitis in the 
first 2 years of life. We further investigated which factors, polymorphisms or a genotype-
prenatal farm environment interaction, could influence the TLRs gene expression.  
Methods  
961 children participated in the prospective longitudinal birth cohort study PASTURE 
(Protection against allergy: study in rural environment) from rural areas of 5 European 
countries (Austria, Finland, France, Germany and Switzerland). Doctor diagnosis and 
symptoms of atopic dermatitis were reported by the parents from 1 to 2 years of age by 
questionnaires. Data on farm exposures during pregnancy were obtained from the 
questionnaire completed at the end of the pregnancy. Gene expression of TLRs and CD14 
as well as polymorphisms in TLRs were assessed in cord blood of these children.  
Results 
The expression of TLR5 and TLR9 was significantly reduced in children with atopic dermatitis 
in the first 2 years of life compared to children with no dermatitis. The same tendency was 
observed with TLR1, 2, 4, 6, 7, 8 and CD14. The children with an expression of TLR5 or 
TLR9 in the upper tertile had a 50% reduced risk to develop atopic dermatitis in the first 2 
years of life (adjusted OR and 95%CI: TLR5: 0.51, 0.32 to 0.81; TLR9: 0.47, 0.30 to 0.75) 
compared to children with an expression in the lower tertile. Prenatal farming environment 
such as maternal contact to farm animal during pregnancy had a protective effect on atopic 
dermatitis in the first 2 years of life. Polymorphisms in TLR5 and TLR9 did not modify the 
level of TLR5 and TLR9 mRNA from cord blood samples. However, among farmer children, 
TLR5 and TLR9 mRNA expression level was higher compared to non-farmer children with 
the respect of TLR polymorphisms.  
Conclusion 
Children with higher expression of TLR5 and TLR9 in cord blood have a reduced risk of 
atopic dermatitis in the first 2 years of life. The upregulation of these receptors of the innate 
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immunity might be mediated by the interaction between genotypes and prenatal farming 
environment.  
 
Introduction  
Atopic dermatitis is a chronic inflammatory, pruritic, skin disease, often occurring in early 
infancy, that affects up to 20% of the children in industrialized countries1. Asthma develops in 
approximately 30% of children with atopic dermatitis, and allergic rhinitis in 35%2. According 
to the International Study of Asthma and Allergies in Childhood (ISAAC), the prevalence of 
symptoms of atopic dermatitis in children six or seven years of age during a one-year period 
varied from less than 2% in Iran and China to approximately 20% in Australia, England, and 
Scandinavia1. The aetiology of atopic dermatitis is complex and involves an interaction 
between genetic and environmental factors as well as the immune system. The hygiene 
hypothesis has contributed to the understanding of allergic disease, suggesting that the lack 
of microbial exposure may increase the risk of atopic disease. A protective effect of microbial 
exposure on asthma has been often described3-5. However, epidemiological evidence 
supporting the association with atopic dermatitis remains inconsistent6-8.  
 
Based on the hygiene hypothesis it has been suggested that an altered stimulation of the 
innate immune system might influence the development of allergic diseases.  Activation of 
the innate immune system is mediated by pattern recognition receptors (PRRs), such as Toll-
like receptors (TLRs), which are present on immune and epithelial cells and recognize 
pathogen-associated molecular pattern (PAMPs). Morever, several findings indicate that 
environmental factors with high level of microbial components may interact with TLR 
polymorphisms on the development of allergic disease9. In a previous study it has been 
shown that prenatal exposure to farm environment has a protective effect on atopic 
sensitization in children and leads to an increased expression of innate immunity receptors10. 
 
Moreover, in humans, polymorphisms in TLRs have been shown to be associated with 
asthma11-13. Recently an association between TLR9 promoter polymorphism and atopic 
eczema has been reported14. 
 
Previous studies have suggested that gene expression of receptors of the innate immune 
system is upregulated by exposure to environment rich in microbial compounds. One study 
has shown that farmer children have an increased expression of TLR2 and CD1415. In 
addition, several studies have demonstrated that farm lifestyle provides a protective 
environment against the development of allergic diseases3,16. However, the direct correlation 
between presence of allergic disease in children and TLR or CD14 expression was not 
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made. Defining if there is a difference of gene expression could allow a better understanding 
of the determinants of atopic dermatitis. 
 
In this study, as gene expression of innate immunity receptors reflects both genetic and 
environmental influences, we examined if TLRs and CD14 expression in cord blood samples 
was associated with the development of atopic dermatitis in the first 2 years of life within a 
prospective birth cohort, the Protection against Allergy-Study in Rural Environments 
(PASTURE) study. In addition, we evaluated the prenatal effect of environmental exposures 
related to the hygiene hypothesis on atopic dermatitis. We further investigated whether TLR 
polymorphisms or prenatal farm environment or the interaction between them modifies the 
expression of these receptors.  
 
Method   
Study design 
The PASTURE study is a prospective birth cohort study involving children from rural areas in 
5 European countries (Austria, Finland, France, Germany and Switzerland), designed to 
evaluate risk factors and preventive factors for atopic diseases. The design of this cohort has 
been described in detail elsewhere17. Briefly, pregnant women were recruited during the third 
trimester of pregnancy and divided in two groups. Women who lived or worked on family-run 
farms where any kind of livestock was kept were assigned to the farm group. The reference 
group was composed of women from the same rural areas not living or working on a farm. 
The questionnaires developed within the PASTURE study group used questions on various 
exposures from the International Study of Allergy in Childhood (ISAAC), the Allergy and 
Endotoxin (ALEX) study, and the Prevention of Allergy Risk factors for Sensitization in 
children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) study. Questionnaires 
were administered in interviews or self-administered to the mothers at the end of pregnancy, 
when the children were 2, 12, 18 and 24 months of age.  
Study population  
Children from the PASTURE birth cohort with data available on atopic dermatitis between 1 
and 2 years of age (n=961). Among these children, 818 have data available on the mRNA 
analysis in cord blood samples and 863 on TLR polymorphisms.  
Definitions 
Symptoms of atopic dermatitis are reported by the parents in the questionnaires at 12, 18 
and 24 months of age. Atopic dermatitis symptom was considered present, when the child 
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had once in the first 2 years of life the presence of an itchy rash on at least at one or more of 
the following locations: face, neck, elbows or behind the knees, joint of hands or feet. 
Children were labelled having doctor diagnosis atopic dermatitis when the parents reported 
at least once in the first 2 years of life a doctor diagnosis atopic dermatitis. 
Farmer children were defined as children whose parents answered positively to the question 
‘does your child live on a farm?’ and whose family ran the farm. Data on farm exposure, 
smoking during pregnancy, the mode of delivery, gender, birth weight, gestational age, 
breastfeeding, and farm milk consumption were obtained from the self-reported 
questionnaires at the 3rd trimester of pregnancy, at 2 months after birth and at 1 year of age. 
Maternal atopy was defined as ever had asthma or hay fever, which information were self-
reported. 
Genotyping of different single nucleotide polymorhisms (SNPs) 
Genotyping of different SNPs was performed as described previously18. In brief, genomic 
DNA was extracted from whole blood and a primer extension preamplification (PEP) method 
was applied to reduce the amount of DNA necessary for the analysis. Next, two polymerase 
chain (PCR) reactions were performed: First, a standard PCR reaction using forward/reverse 
primers and dNTPs. Then, after removing of excessive dNTPS by shrimp alkaline 
phosphatase, a base-specific extension PCR was carried out, using extension primers and 
mass-modified nucleotides. Reaction solution was dispensed onto a 384-format SpectroChip 
(Sequenom) prespotted with a matrix of 3-hydroxypicolinic acid by using a SpectroPoint 
nanodisenser (Sequenom). A matrix-assisted laser desorption ionization time-of-flight mass 
spectrometer (MALDI, Bruker) was used for data acquisitions from the SpectroChip. 
Genotyping calls were made in real time with MassArray RT software (Sequenom). Derived 
genotype frequencies were compared with the expected allelic population equilibrium based 
on the Hardy-Weinberg equilibrium test to control for technical genotyping errors. cDNA was 
amplified by using an iCycler (Bio-Rad, Hercules, Calif) in duplicate, with 18s as a reference 
gene. Polymorphisms in TLR5 (n=3) and TLR9 (n=2) were selected as previously 
described19. These SNPs were as follows: TLR5/T1845C (rs5744174), TLR5/C1173T 
(rs5744168), TLR5/A1774G (rs2072493), TLR9/T-2622C (rs5743836), TLR9/T-2871C 
(rs187084).  
Expression of Toll-like receptors and CD14 
Total RNA was isolated by using the PaxGene RNA Blood Kit (Qiagen, Hilden, Germany) 
supplemented with RNase-free DNase (Qiagen). For reverse transcription (RT), 600ng of 
total RNA in a final volume of 60µl were used and adequate amounts of TaqMan® Reverse 
Transcription Reagents (Applied Biosystems, Foster City, USA) were added. The running 
conditions were as follows: 10 min 25°C; 40 min 42°C; 5 min 95°C. All PCR reactions were 
 55 
analyzed on an ABI Prism 7900 Sequence Detection System (Applied Biosystems) with the 
following running conditions: 45x (2 min 50°C; 10 min 95°C; 15 sec 95°C; 1 min 60°C). The 
used predeveloped primer/probes (Applied Biosystems) are listed in Table 1. The data 
presented are normalized values for the endogenous control (18S rRNA and β2 
microglobulin). TLR3 expression was excluded from the analyses as the expression level 
was less than the detection limit on most of these cord blood samples.  
 
Table 1: Primer/probe assay 
Assay ID Gene 
Hs00413978_m1 TLR1 
Hs00610101_m1 TLR2 
Hs00152933_m1 TLR3 
Hs00370853_m1 TLR4 
Hs00152825_m1 TLR5 
Hs00271977_s1 TLR6 
Hs00152971_m1 TLR7 
Hs00607866_mH TLR8 
Hs00370913_s1 TLR9 
Hs00169122_g1 CD14 
Hs99999907_m1 β2 microglobulin 
Hs99999901_s1 18S rRNA 
 
Statistical analysis 
Data analysis was conducted using SAS software version 9.1 (SAS Institute, Inc., Cary, NC). 
In this study, both definition of atopic dermatitis, doctor diagnosis and symptom present at 
least once in the first 2 years of life, were used. Association between mRNA gene expression 
in cord blood and at 1 year of age and atopic dermatitis (doctor diagnosis and/or symptom) 
was analysed by logistic regression, crude analysis and adjusted for the potential 
confounders. Linear regression was performed to analyse the association between 
polymorphisms in TLR and mRNA gene expression, crude analysis and adjusted for the 
potential confounders. The association was stratified according to the atopic dermatitis 
status, in order to see if there is an interaction with genotypes on the gene expression. 
Associations are presented as exponentiated regression coefficients (geometric means 
ratios: GMR) for numeric data. The following factors were considered as potential 
confounders (= extraneous variable that correlates (positively or negatively) with both, the 
dependent variable and the independent variable): farming status, mother with history of 
asthma or hay fever, gender, the number of older siblings, smoking during pregnancy and 
the centre. Heterogeneity among centres was tested by meta-analysis and when the test for 
heterogeneity was significant, the model was adjusted for centre as a random effect 
estimate, and if there was no heterogeneity as a fixed effect estimate. Estimates of 
cumulative incidence of atopic dermatitis in the first 2 years of age were calculated by the 
Kaplan-Meier method. The Cox proportional hazard model was used to analyze the relation 
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between mother living and being active on a farm during pregnancy and atopic dermatitis. A 
p-value below 0.05 was considered to be statistical significant. 
 
Results  
General characteristics 
The characteristics of the study population showed no difference of the distribution of farmers 
and non farmers between the 5 centers (Table 2). Among children in the non farmer group, 
the frequency of parents with allergy and the mothers smoking during pregnancy were higher 
compared to the children in the farmer group. Among farmer children, the numbers of 
siblings, breastfeeding at 2 months of age and the consumption of farm milk in the first year 
of life were higher compared to non-farmer children. For the other characteristics, there were 
no differences depending on the farming status.  
At 1 year of age, the prevalence of doctor diagnosis atopic dermatitis was 10.8% and of 
atopic dermatitis symptom, 15.1% (data not shown). In the 2 first years of life, the cumulative 
prevalence of doctor diagnosis atopic dermatitis increased until to 17.9% and of atopic 
dermatitis symptom, to 25.8%, (Table 2). These cumulative prevalences for symptoms as 
well as for doctor diagnosis of atopic dermatitis were lower in farmer children compared to 
non-farmer children. However, the differences were not significant.  
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Table 2 Characteristics of the study population and prevalence of atopic dermatitis according to farming status 
 Total study population 
 
N=961 
Farmer  
 
N=454 
Non farmer 
 
N=505 
 %      (n) %      (n) %      (n) 
Girl  49.5   (475) 48.9   (222) 50.1   (253) 
Centre 
A: (Austria)  
C: (Switzerand) 
F: (France) 
G: (Germany) 
S: (Finland) 
 
20.8   (200) 
21.3   (205) 
17.4   (167) 
22.6   (217) 
17.9   (172) 
 
20.0   (91) 
20.7   (94) 
17.4   (79) 
22.0   (100) 
19.9   (90) 
 
21.6   (109) 
21.8   (110) 
17.4   (88) 
23.2   (117) 
16.0   (81) 
Parents with atopy history 
   None  
   One parent 
   Two parents 
 
52.0   (498) 
39.3   (376) 
  8.7   (83) 
 
61.5   (279) 
33.5   (152) 
  5.0   (23) 
 
43.4   (218) 
44.6   (224) 
12.0   (60) 
Mode of delivery: 
   Vaginal delivery 
   Cesarean section 
 
82.5   (786) 
17.5   (167) 
 
82.3   (372) 
17.7   (80) 
 
82.6   (414) 
17.4   (87) 
Birth weight 
    <2500g 
   2500-4500g 
   >4500g 
   
  1.5   (14) 
96.0   (921) 
  2.5   (24) 
 
  1.8   (8) 
95.2   (432) 
  3.1   (14) 
 
  1.2   (6) 
96.8   (489) 
  2.0   (10) 
Nb of siblings: 
   0 
   1-2 
   ≥3 
 
37.5   (360) 
52.7   (506) 
  9.8   (94) 
 
27.1   (123) 
56.4   (256) 
16.5   (75) 
 
46.7   (236) 
49.5   (250) 
  3.8   (19) 
Breastfeeding at 2 month 
   Yes, only 
   Yes, not only 
   No 
 
66.2   (586) 
15.4   (136) 
18.4   (163) 
 
64.4   (268) 
19.5   (81) 
16.1   (67) 
 
67.8   (318) 
11.7   (55) 
20.5   (96) 
Farm milk in 1st yr 31.4   (300) 55.4   (251)   9.7   (49) 
Mother smoking during pregnancy 12.9   (124)   7.7   (35) 17.4   (88) 
Symptoms of Atopic Dermatitis 
Cumulative prevalenceª 25.8   (246) 25.2   (114) 26.2   (131) 
Dr diagnosis Atopic Dermatitis 
Cumulative prevalenceª 17.9   (172) 16.7   (76) 18.8   (95) 
ªCumulative prevalence from 1 to 2 years of age 
 
Association between mRNA expression and atopic dermatitis 
Children with doctor diagnosed atopic dermatitis have a significantly decreased expression of 
TLR5 and TLR9 in cord blood (adjusted GMR and 95%CI: 0.64, 0.47 to 0.88 and 0.67, 0.51 
to 0.90, respectively). The same tendency is observed with TLR1, 2, 4, 6, 7, 8 and CD14 but 
not statistically significant (Fig. 1A). None of the confounding factors (maternal atopy, 
gender, siblings, maternal smoking during pregnancy, centre) had a major influence on the 
results. Among children with atopic dermatitis symptoms, as the outcome, the level of TLR5 
and TLR9 expression was also strongly reduced compared to children without symptoms, 
even though not statistically significant (Fig. 1B). The level of TLRs mRNA was categorised 
in tertiles and the association with atopic dermatitis was analyzed with the lower category as 
the reference. The risk to develop atopic dermatitis in the first 2 years of life in children with a 
level of TLR5, TLR9 or CD14 expression in the upper tertile was reduced by around 50% 
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(adjusted OR and 95%CI: TLR5: 0.51, 0.32 to 0.81; TLR9: 0.47, 0.30 to 0.75; CD14: 0.56, 
0.35 to 0.88) compared to children with an expression in the lower tertile (Table 3).  
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Figure 1. Geometric mean ratio* of TLRs and CD14 expression in cord blood in children with doctor 
diagnosis of atopic dermatitis (A) and in children with symptoms of atopic dermatitis (B) in the 2 first years 
of life 
*adjusted for farmer, atopic mother, gender, older siblings, smoking during pregnancy and centre 
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Table 3. Association between TLRs or CD14 expression categorized in tertile and atopic dermatitis 
 
 Doctor diagnosed Atopic Dermatitis  
 
 
OR* (CI 95%) 
TLR1 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.69 
0.78 
1.00 
 
0.44-1.10 
0.49-1.24 
- 
TLR2 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.66 
0.91 
1.00 
 
0.42-1.05 
0.58-1.42 
- 
TLR4 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.64 
1.00 
1.00 
 
0.40-1.03 
0.64-1.55 
- 
TLR5 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.51 
0.69 
1.00 
 
0.32-0.81 
0.45-1.07 
- 
TLR6 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.71 
0.91 
1.00 
 
0.45-1.13 
0.58-1.43 
- 
TLR7 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.69 
0.67 
1.00 
 
0.44-1.08 
0.42-1.05 
- 
TLR8 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.66 
1.03 
1.00 
 
0.41-1.06 
0.67-1.60 
- 
TLR9 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.47 
0.61 
1.00 
 
0.30-0.75 
0.39-0.95 
- 
CD14 
     Upper tertile 
     Middle tertile 
     Lower tertile, ref. 
 
0.56 
0.66 
1.00 
 
0.35-0.88 
0.42-1.04 
- 
*adjusted for farmer, atopic mother, gender, older siblings, smoking during pregnancy and centre 
 
 
Association between polymorphisms in TLR5 and TLR9 and mRNA gene expression  
Table 4 shows the genotype frequencies of the 5 investigated TLR5 and TLR9 
polymorphisms. Genotype frequencies did not differ between farmer and non farmer children.  
Mean gene expression of TLR5 was similar in TLR5/T1845C, TLR5/C1173T, or 
TLR5/A1774G genotypes. There was also no difference of mean gene expression of TLR9 
between TLR9/T-2622C and TLR9/T-2871C genotypes (Fig. 2).  
Moreover, the difference of gene expression of TLR5 and TLR9 between children with atopic 
dermatitis and children with no atopic dermatitis was not modified by these genotypes 
variants.  
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 Birth N=863    %      (n) 
Farmer N=406 
   %      (n) 
Non farmer N=457 
   %      (n) 
TLR5_T1845C 
     TT 
     TC 
     CC 
 
32.9 (279) 
49.2 (418) 
17.9 (152) 
 
35.5  (141) 
47.4  (188) 
17.1  (68) 
 
30.5  (138) 
50.9  (230) 
18.6  (84) 
TLR5_C1173T 
     CC 
     CT 
     TT 
 
88.3 (762) 
11.1 (96) 
  0.6  (5) 
 
88.4  (359) 
10.6  (43) 
  1.0  (4) 
 
88.2  (403) 
11.6  (53) 
  0.2  (1) 
TLR5_A1774G 
     AA 
     AG 
     GG 
 
71.8  (607) 
26.7  (226) 
  1.5  (13) 
 
73.7  (291) 
25.1  (99) 
  1.3  (5) 
 
70.1  (316) 
28.2  (127) 
  1.8  (8) 
TLR9_TMIN2622C 
     TT 
     TC 
     CC 
 
75.9 (652) 
22.6 (194) 
  1.5   (13) 
 
75.8  (304) 
22.9  (92) 
  1.3  (5) 
 
76.0  (348) 
22.3  (102) 
  1.8  (8) 
TLR9_TMIN2871C 
     TT 
     TC 
     CC 
 
31.1 (265) 
50.6 (432) 
18.3 (156) 
 
32.9  (131) 
47.2  (188) 
19.9  (79) 
 
29.5  (134) 
53.6  (244) 
16.9  (77) 
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Figure 2. Association between polymorphisms 
in TLR5 (A) and TLR9 (B) and TLRs gene 
expression stratified for atopic dermatitis status. 
 
Table 4. TLR5 and TLR9 polymorphisms. SNPs on different gene positions are depicted in the left 
column. TT means homozygous for thymine, TC heterozygous for thymine.  
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Association between prenatal farm exposure and atopic dermatitis  
The cumulative incidence of doctor diagnosed atopic dermatitis at the age of 2 years in the 
total population was 17.3% (Fig. 3A). Among children with mother living and active on a farm 
during pregnancy 
this cumulative inci-
dence was lower 
compared to 
children with mother 
not living and active 
on a farm during 
pregnancy (14.6% 
and 19.0%, re-
spectively and 
hazard ratio 0.69; 
95% CI 0.49 to 0.99, 
Fig. 3B).  
Moreover, we found 
a significant ne-
gative association 
between the 
increasing numbers 
of animal species 
the mother had 
contact during 
pregnancy and the 
presence of atopic 
dermatitis in the first 
2 years of life (Fig. 3C).  
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Figure 3. Association between prenatal farm 
exposure and the development of atopic dermatitis 
in children in the first 2 years of life.  
A: Association between the incidence of doctor 
diagnosis for atopic dermatitis and age of the 
children.  
B: The incidence of doctor diagnosed atopic 
dermatitis at age 1, 1.5 and 2, when the mother was 
living and being active on a farm during pregnancy.  
C: Association between the increasing numbers of 
species the mother had contact during pregnancy 
and the presence of atopic dermatitis in the first 2 
years of life.  
B 
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Effect of TLR5 and TLR9 genotypes and farming status on gene expression of TLR5 (a) and 
TLR9 (b) in cord blood 
As we have shown before, the gene expression of TLR5 and TLR9 did not varied with 
genotypes. Moreover the level of TLR5 expression in cord blood was not modified by farming 
status and the mean gene expression of TLR9 was slightly, but not significantly increased in 
cord blood of children with mother living on a farm (data not shown). However, stratification 
by genotypes of TLR5/A1774G and TLR9/T-2622C revealed heterogeneity of the farm effect 
on TLR5 and TLR9 expression, respectively. Children with mother living on a farm and 
having AA genotype in TLR5/A1774G expressed 12% more TLR5 in cord blood compared 
with children with mother not living on a farm. The same significant effect of farming was 
observed in the expression of TLR9 in children having TT genotype in TLR9/T-2622C. In 
contrast, among children with the AG or GG genotypes in TLR5/A1774G and among those 
with the TC or CC genotypes in TLR9/T-2622C, the farm environment did not influence the 
gene expression (Fig. 4). 
 
Figure 4. A: Children, with mothers living on a farm and having an AA polymorphism on position 1774 of the 
TLR5 gene, express more TLR5 compared to children with mothers not living on a farm. GG and AG 
polymorphisms were combined because of small numbers. 
B: Children, with mothers living on a farm and having a TT polymorphism on position 2622 of the TLR9 gene, 
express more TLR9 compared to children with mothers not living on a farm. CC and TC polymorphisms were 
combined because of small numbers. 
AA           GG+AG TT           CC+TC         
 
A B 
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Discussion  
This study shows that children with a higher level of TLR5 and TLR9 expression at birth have 
a decreased risk of atopic dermatitis compared to children with a lower level. Furthermore, 
maternal farming activities and the contact to different farm animals during pregnancy have a 
protective effect on the development of atopic dermatitis.  
 
The difference in gene expression of receptors of innate immunity observed at birth, between 
children who will develop in early life atopic dermatitis and those who will not, suggests an 
influence of prenatal environmental factors. In fact, it was earlier shown that prenatal 
exposure to farm environments protects against atopic sensitization10. TLRs play a pivotal 
role in the induction of first line of defense mechanisms of the innate immune system and 
trigger effective adaptive immune responses to microbial compounds. We have shown in 
chapter A1 that prenatal and early postnatal farm environmental factors increased the 
expression of different TLRs at time of birth and at one year of age. Here, we have also 
observed that genetic variations in combination with farming exposures influence TLR5 and 
TLR9 gene expression, indicating that a gene-environment interaction may exist. Differences 
in gene expression between healthy children and such with atopic dermatitis were 
independent of several single nucleotide polymorphisms (SNPs). However, several SNPs in 
genes encoding for TLRs have been shown to be associated to allergic diseases, especially 
with asthma11-13. In two previous studies, associations between TLR2 and TLR9 SNPs with 
atopic dermatitis have been reported14,20. But these studies included mainly adult patients 
and controls and did not investigate the TLR expression levels as well the environmental 
influences.  
 
The observed differences in TLRs expression concern mainly TLR5 and TLR9. TLR5 
recognizes flagelllin21, found on nearly all motile bacteria and TLR9 recognizes unmethylated 
CpG motifs present in bacterial DNA22. Activation of TLR9 in dendritic cells induces Th1-
based immune response23. Therefore, synthetic CpG and their receptors are prime 
candidates for the prevention and treatment of Th2-associated atopic disorders. In this 
context, the advantage of TLR9 activation with protective effect on Th2 immune responses 
has been already shown in a murine model and in first clinical trials of TLR9-based 
immunotherapies24. Our study indicates that these new therapeutic strategies with activation 
of TLR9 might also have a potential efficacy on atopic dermatitis.  
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Conclusion 
Children with higher expression of TLR5 and TLR9 in cord blood have a reduced risk of 
atopic dermatitis of 50% in the first two years of life, suggesting an in utero effect. We 
observed a protective effect of prenatal farm environment on the development of atopic 
dermatits in children. The upregulation of these receptors of the innate immunity might be 
mediated by the interaction between genotypes and prenatal farm environment. 
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Maternal vitamin D intake during pregnancy increases gene 
expression of ILT 3 and ILT4 in cord blood 
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Abstract 
Background  
Recent studies indicate that prenatal vitamin D intake protects from the development of 
atopic diseases in young children. Vitamin D has been shown to induce tolerogenic antigen 
presenting cells such as dendritic cells. Whether the protective potential of prenatal vitamin D 
is mediated through tolerance induction, however, is unknown.  
Objective  
To evaluate the association between prenatal vitamin D supplementation and tolerogenic 
antigen presenting cells in cord blood as determined by mRNA measurement of 
immunglobulin-like transcripts (ILT)3 and ILT4  
Methods  
A prospective multicenter birth cohort was established in rural areas of five European 
countries. Information on maternal exposures including vitamin D intake was collected by 
questionnaires during pregnancy. The gene expression of ILT3 and ILT4 was analyzed by 
real time PCR in the cord blood of the enrolled children.  
Results 
Maternal vitamin D supplementation during pregnancy was related to an increase in the gene 
expression of ILT4 (p=0.003) and in tendency for ILT3 (p=0.068). This association remained 
significant after adjustment for farming status and gender which were found to be 
independent factors associated with the gene expression of ILT3 and ILT4.  
Conclusions 
Vitamin D supplementation during pregnancy increased mRNA levels of ILT3 and ILT4 in 
cord blood. This may point towards an early induction of tolerogenic immune responses by 
vitamin D.  
 
Contribution to this work 
The PASTURE project was planned and is under coordination of E. von Mutius et al.17. RNA-
isolation, reverse transcription and gene expression measurements were done by myself at 
the Children's Hospital Zürich. Statistical analyses were performed by Mascha Rochat at the 
Children's Hospital (University Munich). The manuscript was written by Mascha Rochat. 
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CHAPTER A4 
 
 
Discussion and outlook 
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The development of allergic diseases such as allergic rhinitis, atopic dermatitis, food allergies 
and allergic bronchial asthma, which are complex inflammatory disorders, is influenced by 
two risk factors: On one hand many gene polymorphisms have been identified in the last few 
years which show an association to one or more manifestations of allergic disorders. On the 
other hand the rapid increase in the prevalence of allergic diseases in industrialized countries 
over the last decades is associated with reduced exposure to bacterial, viral or fungal 
components and changes in subsequent complex gene-environment interactions.  
 
In this work, we proceed with earlier findings from epidemiological studies which have shown 
that farming factors protect against the development of allergies but also reveal that the time 
of exposure is crucial. The longitudinal and prospective design of the PASTURE study 
allowed us to investigate pre and early postnatal factors on the development of the innate 
immunity as first line of defence against microbial compounds. Indeed, our results provide 
additional evidence of the importance of early stimulation: Working on a farm during 
pregnancy affected the expression of different TLRs at time of birth (Chapter A1) and was 
associated with a reduced incidence to develop atopic dermatitis in the first two years of life 
(Chapter A2). Early consumption of farm milk, especially unboiled farm milk, influenced the 
TLR-expression at one year of age (Chapter A1).  
What are the farming factors which have the impact to influence TLRs very early in life? It 
seems likely that the farm area is rich in various microorganisms which are detected by 
receptors of the innate immunity. Investigation on mattress dust and animal shed dust 
samples identified a great diversity where Bacillus spp and coliform bacteria were the most 
prominent microorganisms1. Higher levels of lipopolysaccharide2,3 (cell wall components of 
Gram-negative bacteria), muramic acid4 (part of cell wall of all bacterial species) and 
bacterial DNA, rich in hypomethylated CpG motifs5 have also been identified to be much 
higher in farming environments, exerting an anti-allergic effect. However, whether one or 
more bacterial-derived compounds may be directly responsible for the observed allergy-
preventing effects cannot be proven in epidemiological analysis. Well-defined experiments, 
including in vitro and in vivo laboratory animal studies, are essential to verify the relationship 
between exposure to certain bacterial-derived substances and the underlying mechanisms, 
leading to protection against allergic immune responses. First investigations were made by 
Vogel et al. recently, who studied immune responses, elicited by Bacillus licheniformis 
spores in vitro and in vivo. This is the predominant Bacillus species, which was found in 
children`s mattresses and animal sheds. Some immunostimulatory activity of Bacillus spores 
could clearly been demonstrated, including an increased Th1-cytokine profile after 
stimulation of PBMCs and human monocyte-derived dentritic cells and a decreased numbers 
of eosinophils and reduced mucus-producing goblet cells in a murine allergic asthma model1.  
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These results support our findings that there is possibly a way to develop a vaccine-like 
therapeutic agent for the pre- or early postnatal phase, which has the efficiency to stimulate 
the innate immunity and protects against allergic diseases. In the past, the association of 
probiotica supplementation during pregnancy and early infancy and the incidence of allergic 
rhinitis or asthma during childhood was investigated intensively6-11. However, the results are 
not consistent and the most beneficial probiotic strain or the composition of different 
probiotics and/or prebiotics have to be determined.  
 
We focused our study about early environmental exposure on the expression of TLRs 
because these receptors operate as key sensors of invading pathogens in innate immune 
defenses and are important initiators of subsequent immune responses. Beside TLRs, NOD-
like receptors (NLRs), especially NOD1 and NOD2 are known to recognize components of 
Gram-positive and Gram-negative bacteria12-14 (see also Introduction). Further analysis with 
focus on NOD1 and NOD2 gene expression is now carried out for a better understanding of 
pre- and early postnatal farming exposure influences on the development of innate immune 
receptors. 
 
Recently, Prescott et al.15 studied the association of cytokine responses after stimulation of 
cord blood mononuclear cells with TLR ligands and the diagnosis of allergic diseases at one 
year of age. Children with allergic symptoms were characterized to have significantly higher 
TNF-α and IL-6 levels in response to TLR2, TLR4, and TLR5 activation, which might suggest 
differences in downstream intracellular events that drive cytokine production in subsequently 
allergic children. The PASTURE study provides the possibilities to investigate in a 
longitudinal way the expression of members of the signalling cascade, which activate the 
subsequent cytokine production. However, we have realized that the enormous amount of 
data and the complexity of the regulatory network of the innate immunity, necessitates 
suitable alternative methods for data analysis. Popular and interesting tools for gene 
expression analysis are clustering methods which are used to place data elements into 
related groups without advance knowledge of the group definitions16-18. Further data analyses 
including such methods have to be realized in the future.  
 
In the past, epidemiological studies contributed to a better understanding of gene-
environment interaction and the outcome of immune responses, especially in context of 
allergic diseases. Such studies provide the advantage to investigate conditions over a period 
of time, which can hardly be simulated in the lab. A good strategy for investigations and 
experiments, a close cooperation of different centres, laboratories and fieldworker, as well as 
sufficient funds, are essential requirements for success. Although the PASTURE-study ran 
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since 2002, we are only at the beginning of the results that are arising from this prospective 
study design. Investigation of the maturing innate immune system but also B- and T- cell 
responses in 4.5 years old children are the following steps, which will contribute to further 
insights in the complex network of the immune system. 
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Abstract 
Attenuated Salmonella enterica serovar Typhimurium is an interesting organism for 
vaccination studies due to the stable and efficient expression of heterologous antigens in the 
mucosal digestive tract. We hypothesized that attenuated Salmonella delivering the model 
allergen ovalbumin could also be a suitable tool to prevent ovalbumin-induced food allergy in 
mice. In this study we tested the allergen expression in different attenuated Salmonella 
strains and investigated furthermore the influence of pre-treatment with such bacteria on the 
development of allergic symptoms in a murine ovalbumin allergy model. Our data indicate 
that the prophylactical gavage of attenuated Salmonella expressing ovalbumin could protect 
against food-induced allergy. 
 
Introduction 
In developed countries, food allergy has increased in the past 10-15 years and up to 8% of 
children less than 3 years of age and approximately 2% of the adult population suffers on 
food allergy1. The development of new therapeutic or preventive treatments, beside the 
present method of identification and avoidance of triggering foods, and reactionary therapy in 
the event of anaphylaxis, is enforced. Although there are various promising results observed, 
each trial has its limitations. Several attempts of subcutaneous, sublingual or oral 
immunotherapies, which are partly used successfully for other forms of allergic diseases aim 
to alter the allergic response to the causal protein without side effects. The advantage of 
these approaches is that the food can be consumed without symptoms. Although attempts of 
subcutaneously delivered allergen immunotherapy resulted in a Th1-dominant immune 
response, significant adverse effects, including recurrent anaphylaxis has been observed2. 
An interesting tool for mucosal immunization is the use of attenuated live bacteria species 
such as Salmonella. Attenuated Salmonella are described as a carrier system for the in vivo 
delivery of eukaryotic expression plasmids3. SL2707 aroA mutant Salmonella strain is well 
characterized in murine immunization studies and was first described as non-virulent and 
safe carrier strain in 19814. Meanwhile, humoral and cellular immune response of aroA 
mutant Salmonella carrier strains in vaccine immunization studies was investigated 
extensively5-9 and, recently, first results with the use of Salmonella in food allergy studies 
were published10. It was reported that the balance of attenuation of virulence and penetration 
of the host seems to be an important parameter, since it was observed that carrier strains 
expressing high levels of heterologous antigens will be over-attenuated and lose their 
immunogenicity11,12. Thus, the interest has increased to generate further attenuated 
Salmonella Typhimurium strains. Strains deleted in htrA (high temperature requirement), in 
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galE (encode UDP-galactose 4-epimerases), purD (purine synthesis), or recA (necessary for 
DNA repair) were constructed and described as highly attenuated13.  
The aim of this study was to investigate the expression of a chromosomal or plasmid 
encoded model allergen (ovalbumin), by different attenuated Salmonella strains. 
Furthermore, we suggest that prophylactical gavage with attenuated Salmonella modified 
genetically to express ovalbumin (OVA) allows protection against OVA-induced food allergy. 
 
Methods: 
Bacterial strains and culture conditions 
Salmonella Typhimurium strains and plasmids used in this study are listed in Table 1 and 2, 
respectively. Bacteria were routinely cultured in Luria-Broth (LB, MP Biomedicals), Terrific 
Broth (TB, QBiogene) and on LB agar (Becton Dickinson) plates. If required for the selection 
or to maintain plasmids, ampicillin (100 µg/ml) and/or kanamycin (50 µg/ml) were added. All 
bacterial strains used are attenuated through mutations in genes essential for aromatic 
amino acid synthesis (aroA), purine biosynthesis (purD), lipopolysaccharid (LPS) synthesis 
(galE), homologous recombination (recA) or virulence (sseC) and phoN. Bacterial strains 
were obtained from Dr. Michael Hensel (Erlangen, Germany). 
 
Table 1: Bacterial strains and their characteristics 
Strains Mutation OVA gene location Promoter References/Source 
MvP457 purD chromosomal constitutive 14 
MvP464 phoN chromosomal constitutive  14 
MvP478 galE chromosomal constitutive  14 
SL7207 aroA no  15 
MvP103 sseC no  14 
Mvp455 recA no  13 
 
Table 2: Plasmids and their characteristics 
Plasmid Charakteristic Promoter References 
p2593 low copy plasmid intracellular active 15 
p2631 low copy plasmid constitutive active 15 
 
DNA-Standard methods 
Plasmid DNA isolation was performed using either the NucleoSpin Plasmid Kit (Macherey 
and Nagel) or the QIAGEN Maxi kit. The QIAGEN PCR purification kit was used for the 
purification of PCR-products, the QIAquick gel extraction kit was used for extraction of DNA-
fragments from agarose gel. All steps were performed according to the manufacturer′s 
protocol. The transfer of plasmid-DNA into different strains of Salmonella was mediated by 
electroporation. Cells were transferred into a chilled electroporation cuvette and shocked with 
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17kV/cm, 200 Ω and 25µF. For preparation of electrocompetent Salmonella strains, 250 µl 
overnight culture was incubated in 12 ml TB medium until OD595 of 2. Cells were centrifuged 
four times at 6000 g at 4°C and washed with 10 ml cold H2O. Subsequently cells were 
resuspended in 200 µl 10% glycine (Sigma) and stored on ice until transformation. 
Amplification and sequencing of DNA 
To verify the presence of the OVA gene in plasmids, Polymerase-Chain-Reaction (PCR) and 
sequencing were carried out. The used oligonucleotides are listed in table 3, and were 
synthesized by Microsynth (Switzerland). PCR for sequencing reactions was done using 
BigDye Terminator v3.1 Cycle Sequencing Kit from Applied Biosystems. In brief, 4 µl of 
BigDye Reaction Mix and 2 µl of sequencing buffer were added to 10 pmol of the primer and 
200-500 ng of the plasmid to be sequenced. Aqua dest. was added to reach 20 µl of reaction 
volume. After PCR reaction, PCR products were loaded on a Sephadex G-50 column and 
centrifuged to remove unused dNTPs. Sequences were analyzed using ABI PRISM 310 
Genetic Analyzer and ABI PRISM data collection software (Applied Biosystems). Results 
were evaluated manually by sequence comparison.  
 
Table 3: Oligonucleotides used in this study 
Designation Sequence Application 
Ova FwI 5`-ATT CAA GGA GCT CAA AGT CCA CCA TGC-3`  PCR/Sequencing 
Lac-Ova-For-EcoRI 5` GAA TTC GCG GAT TAA CAA TTT CAC AC-3` PCR/Sequencing 
Ova RevI 5`GGG AGG AGA AAC ACA TCT GCC AAA G-3` PCR/Sequencing 
Ova-Rev-SmaI 5`GGG AGG AGA AAC ACA TCT GCC AAA G-3` PCR/Sequencing 
 
Bacterial infection of macrophages and allergen expression 
The murine macrophage cell line RAW264.7 (European Collection of Cell Cultures, UK) was 
cultured in Dulbecco`s modified Eagle medium (DMEM, GIBCO) containing 10 % heat-
inactivated fetal calf serum (FCS, PAA/Omnilab) and 1% Antibiotics/Antimycotics (AB/AM, 
GIBCO) at 37°C at an atmosphere of 5% CO2. The cells were suspended in 24-well plates at 
a density of 5 x 104 cells per well. 
For the infection of RAW264.7 cells, Salmonella strains were grown to stationary phase in LB 
with the appropriate antibiotic selection. The OD600 of the cultures was adjusted with LB to 
0.2 and the bacteria were washed once with phosphate-buffered saline (PBS, GIBCO). 
Bacteria were diluted in cell culture media and added to the cells growing in 24-well culture 
plates at a multiplicity of infection (MOI) of about 10. To synchronize infection, the plates 
were centrifuged at 500 rpm for 5 min and incubated for 25 min at 37°C in an atmosphere 
containing 5 % CO2. After infection the macrophages were washed three times with PBS and 
incubated for 3 h in cell culture medium containing 100 µg/ml gentamicin (Sigma). The cells 
were washed once with PBS and lysed with 0.1% Triton X-100 for 10 min at RT and 
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centrifuged for 1 min at 1200 rpm. The intracellular expression of OVA was analyzed by 
Western blot analysis. 
Protein analysis and Western blotting 
Proteins were separated by SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) according 
to Laemmli16, using 5% stacking and 10% separating gels.  
Proteins were transferred onto nitrocellulose-membrane (Protan BA85, Schleicher & Schüll) 
by wet blotting procedure, using 10 x transfer buffer (0.27 M Tris, 2 M Glycin, 1% SDS, 20% 
Methanol). The electrotransfer was performed for 40 min at 0.35 A. The membrane was 
blocked by incubation in 5% powder milk in TBST over night. OVA was detected by 
incubation with the primary rabbit anti-OVA antibody (Chemicon) and subsequent incubation 
with secondary antibody anti rabbit IgG (Goat conjugated to horse-radish-peroxidase (HRP, 
Amersham Bioscience, diluted in TBST for 1 hour at room temperature (RT). The membrane 
was washed 3-5 times with TBST after each incubation step. Protein was detected by 
chemiluminescence using ECL system (Amersham Bioscience). 
Mice sensitization to OVA, oral administration of Salmonella and oral challenges 
Female C3H/HeJ mice were purchased from Jackson Laboratory (USA). All mice were kept 
at the Animal Facilities of the University of Geneva School of Medicine under specific 
pathogen-free conditions. Animals were used 4-6 weeks of age and were fed with standard 
mice pellets without OVA.  
A murine model of food allergy was used as published earlier by Li XM et al17 and Frossard 
CP et al18. Mice (totally 15 animals, 5 per group) were sensitized orally at days 0, 7, 14, and 
21 with 20 mg OVA (Sigma) and 10 µg cholera toxin (List Biological Laboratories) in PBS. 
For bacterial treatment, Salmonella were grown over night until mid-log phase. Bacteria were 
then harvested by centrifugation (4500 rpm) and resuspended in PBS. 109 CFU/mouse in a 
volume of approximately 200 µl were given on three days prior each oral sensitization step 
(Fig. 1), using a round-tip stainless steel needle. Two groups of control mice were 
administered either with PBS or with plasmidless bacteria. On day 28 all mice were 
challenged by intragastric gavage with 50 mg OVA and observed 30 min until they were 
sacrificed with CO2. Anaphylaxis was graded using a symptom score, described by Frossard 
et al.18. Score 0: no symptoms, normal activity; score 1: decreased activity, random 
scratching, myocloni, reversibility of symptoms within 5 min; score 2: marked decreased 
reactivity, continuous scratching, abnormal breathing, reversibility of symptoms within 10 
min; score 3: low reactivity or absence of reactivity, abnormal breathing, death, or no 
reversibility of symptoms within 15 min. 
The body temperature was measured before and 30 minutes after the challenge with the 
infrared ear thermometer (Braun, Kronberg, Germany).  
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All experiments were conducted in accordance with the ethical guidelines of Animal Studies 
Ethics Committee. 
Statistical analysis 
Values are presented as the mean ± standard error. The significance of body temperature 
and symptom score was analyzed by linear regression, using SPSS software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Verification of OVA synthesis  
Before starting OVA expression analysis the OVA gene was examined by PCR and 
sequence analysis (data not shown). To verify and to compare the production of OVA, 
mouse macrophages were infected with different Salmonella strains harbouring either OVA 
encoding plasmids or a chromosomal gene cassette. The intracellular amount of OVA was 
analyzed by Western blotting (Fig. 2A and B).  
 
 
 
 
 
 
 
 
 
 
Figure 2. OVA detection in vitro. Mouse 
macrophages were infected with Salmonella 
strains harbouring either OVA-encoding 
plasmids (A) or expression cassette for OVA 
(B). The intracellular amount of OVA was 
analyzed by Western blotting. OVA coded by 
p2593 is regulated intracellularly and 
constitutively by p2631. Strains are stable 
attenuated through mutation in aroA 
(SL2707), galE (MvP464 and MvP478) and 
purD (MvP457). OVA produced by SL2707 
p2593 was only weak detectable. Therefore 
the brightness and contrast were increased.  
      Day:        -3,  -2,  -1       0             4,  5,  6,   7                 11, 12, 13,  14              18,  19,  20, 21                    28   
+ Oral sensitization 
* SL2707 p2631, SL2707 or PBS administration 
Challenge 
* * * * * * 
+ + + + 
* * * * * * 
Figure 1. Experimental protocol: Intragastric ovalbumin sensitization and Salmonella administration. Mice 
were sensitized at day 0, 7, 14, 21 with ovalbumin and choleratoxin. Three groups of mice (five animals per 
group) were fed either with SL2707 p2631, SL2707 or PBS on three days prior each sensitization step and 
challenged on day 28 with OVA.  
OVA 
SL2707 
p2631 
SL2707 
p2593 
A 
negative 
control 
MvP464 MvP457 MvP478 
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B 
negative 
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OVA was detected clearly in macrophages infected with MvP464, MvP478, MvP457 and 
SL2707 p2631 but only weak in SL2702 p2593 and not in MvP460. We further transformed 
p2593 in MvP103 to exclude a strain specific inhibition effect on OVA expression. The 
observed band was also only weakly visible (data not shown).  
Prophylactical treatment of SL2707 p2631  
We decided to use the well described aroA-deficient Salmonella strain harbouring p2631 in a 
first preliminary in vivo sensitization study. The aim of this study was to investigate whether 
the prophylactical gavage of SL2707 p2631 reduce the severity of allergic reactions. 
Therefore we administered bacteria to mice on three days before each sensitization step 
over a period of four weeks. SL2707 without plasmid and PBS served as negative control. 
After the challenge with high dose of OVA the body temperature was measured before and 
30 min after challenge and a symptom score was assessed (Fig. 3A-C). Mice with strong 
anaphylactic symptoms (score 3) have reduced body temperature (mean: 34.5°C) compared 
to mice with no (score 0) or weak (score 1) observed anaphylactic symptoms (score 0, mean: 
35.6°C; score 1, mean: 35.7; Fig. 3A). The correlation between decrease of the body 
temperature and increase of the symptom score was slightly over the significance limit 
(p=0.052; Fig. 3B).  
The highest body temperature 30 min after challenge was observed in the group of mice 
treated with Salmonella SL2707 p2631 (mean: 35.5°C) compared to the PBS group (mean: 
35.1) and Salmonella SL2707 (mean: 34.6°C; Fig. 3C). Furthermore, beside the highest 
measured temperature in the group of mice treated prophylacticaly with SL2707 p2631, 
these animals have had reduced anaphylactic symptoms (mean score 1.4), whereas mice 
treated with PBS or SL2707 have had an identical mean score of 2 (Fig. 3D).  
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Discussion and outlook: 
In the current study, we investigated first the expression of OVA, encoded either 
chromosomally or on plasmids and furthermore we tested the prophylactical gavage of one 
attenuated Salmonella strain in an in vivo experiment. We were able to verify OVA in nearly 
all used constructs. The choice of SL2707 p2631 for use in vivo experiment was based on 
the two following reasons: Although it is already known that chromosomal integration 
provides more stable expression of heterologous antigens13 such a strain might deliver lower 
amounts of heterologous antigens due to the single gene copy compared to plasmid-based 
constructs with multiple copies. Furthermore, we observed that the plasmid-based antigen 
delivery depends on the promoter. This was already earlier described by Husseiny et al. who 
observed a reduced OVA expression under control of the intracellular-activated promoter 
sseA in an aroA carrier strain15.  
Results of our in vivo experiments indicated that mice pre-treated with SL2707 p2631 may 
have a positive and protective effect on allergen induced anaphylaxis, characterized through 
lower mean score and higher body temperature compared to the controls. However, this 
Figure 3. Temperature drop and symptom scores after challenge with OVA.  
Mice sensitized to OVA and pretreated with either PBS, SL2707 or SL2707 p2631 were 
challenged with high dose of OVA and observed for 30 min. The observed anaphylactic 
symptoms were classified in a score system: Score 0: no symptoms, normal activity; score 1: 
decreased activity, random scratching, myocloni, reversibility of symptoms within 5 min; score 2: 
marked decreased reactivity, continuous scratching, abnormal breathing, reversibility of 
symptoms within 10 min; score 3: low reactivity or absence of reactivity, abnormal breathing, 
death, or no reversibility of symptoms within 15 min. 
A and B: Correlation between body temperature decrease and symptom score increase. The body 
temperature of each mouse was measured in the ear twice per mouse. Results in A are presented 
as means ± standard error. For calculation of the p value, a linear regression was done (B).  
C: Body temperature as mean values ± standard error per mouse group before and 30 min after 
challenge. 
D: The observed symptoms 30 min after challenge are graded in a score system. Each point 
corresponds to one mouse.  
PBS SL2707 SL2707 p2631 
C D 
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preliminary experiment was carried out with a small number of animals and did not allow 
wide molecular investigation. Therefore, a new in vivo experiment was planned (chapter B2) 
to provide not only insight into immunological processes but also investigate if the use of 
attenuated Salmonella delivering an allergen is also a suitable tool to treat food allergy. 
Some modifications were carried out for the used construct: Recently a novel combination of 
heterologous antigens fused on effector proteins of bacterial type III secretory system was 
described for a vaccination strategy12. Effector proteins are bacterial virulence proteins 
characterized to be transported from the bacteria cell to the host cell cytoplasm19,20. We 
hypothesized a further improvement of the immune response if the allergen is transported 
directly into the host cell cytoplasm.  
Since it was reported that aroA deficient strains were shown to be reduced in the ability of 
protein synthesis, probably due to the defect in the synthesis of aromatic amino acid, we 
decided to use a recA mutant strain for the following in vivo experiment, which was already 
described as avirulent and sensitive to innate immune defense mechanisms21. 
 
Contribution to this work 
In vitro experiments were designed, performed, and analyzed by myself at the lab of R. 
Lauener at the Childrens's Hospital Zürich. The in vivo experiment was planned by myself 
and carried out together with C. Frossard at the School of Medicine (University of Geneva). 
The manuscript was written by myself.  
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Abstract  
Background 
The strict avoidance of allergenic substances is the common treatment of food allergy. 
Allergen-specific immune therapy, where patients are treated with increasing concentrations 
of the allergen, is a well established method against other allergies, such as hay fever or 
insect sting allergies but not food allergy. Further, exposure to microbial components protects 
against the development of allergic disorders. In this study, we tested whether combined 
intake of microorganisms and low amounts of allergen is a possible method to prevent or 
treat food allergies. 
Methods 
An attenuated Salmonella strain was transfected with a low copy plasmid encoding the gene 
for the model allergen ovalbumin (OVA) fused on the effector protein sseF (p2629) or with a 
control plasmid (p2096). 
Mice were administered Salmonella p2096, Salmonella p2629 or PBS prior to oral 
sensitization with OVA in combination with choleratoxin (prophylactical approach) or after 
sensitization phase (therapeutical approach). A symptom score was generated after oral 
antigen challenge. Allergen-specific antibody titres were measured in serum and feces. 
Levels of T-helper cell populations as well as relative gene expression of different Toll-like 
receptors (TLRs) were determined in lymphnodes.  
Results 
We showed that Salmonella releasing allergen reduced allergic symptoms in mice applied in 
a prophylactic or therapeutic way, along with increased antigen-specific immunoglobulin A 
(IgA) titres and reduced gene expression of TLRs. 
Conclusion 
These results suggest that the combination of microbial stimulation and application of small 
amounts of allergens via intracellular living microorganisms bioengineered to deliver antigen, 
can decrease food-induced anaphylaxis. 
 
Introduction  
Up to 8% of children less than 3 years of age and approximately 2% of adults suffer from 
clinical symptoms of food allergy. The marked increase of allergic diseases in westernized 
countries is associated with wealth, good education and small families as well as reduction in 
infectious diseases. These observations have given rise to the formulation of the ’hygiene 
 87 
hypothesis’, which suggests that limited exposure to bacterial and viral pathogens during 
early life leads to an insufficient stimulation of Th1-cells as well as a reduced activation of T-
regulatory (Treg) cells and a shift to Th2-biased immune responses, resulting in a 
predisposition to allergy1-4. Results of previous cross-sectional studies with farming and non 
farming children have shown that continuous exposure of the immune system to microbes or 
its components, such as lipopolysaccharides (LPS) may protect against allergic symptoms5,6.  
There is no treatment of food allergy, except the strict avoidance of trigger foods and the 
treatment of allergic reactions. Subcutaneously delivered allergen immunotherapy is a well 
established method to treat insect sting allergies or hay fever but not food allergies7.  
Salmonella enterica serovars Typhimurium is a rod-shaped gram-negative bacterium, 
characterized to immigrate and live within cells of the intestine system. The ability of S. 
enterica to enter non-phagocytic cells and survive and replicate intracellularly in phagocytes 
is based on virulence factors encoded by pathogenicity islands (SPI). Two pathogenicity 
islands (SPI1 and SPI2) encode a type III secretion system (T3SS), which is evolutionarily 
related to the flagellar export system and mediates the transfer of bacterial virulence 
proteins, known as effector proteins, from the bacterial cell into the host-cell cytoplasm8,9. 
Many different effector proteins are translocated by the SPI2-T3SS, among them SseF10. 
Attenuated Salmonella are attractive ’live vectors’ and an interesting tool for mucosal 
immunization because this delivering system targets the mucosal-associated lymphoid 
system and brings the expression plasmid in contact with immune cells. 
It was described that Salmonella strains are unstable when harbouring high copy number 
plasmids11. We have used the low copy plasmid pWSK29 which encodes ovalbumin (OVA) 
as a model allergen, fused to the effector protein SseF under control of promoter sseA which 
is activated by Salmonella after uptake by dentritic cells (DCs)12. The aim of this study was to 
evaluate whether the oral gavage of attenuated Salmonella enterica serovar Typhimurium, 
expressing OVA-SseF fusion protein, could modulate allergic symptoms prophylactically as 
well as therapeutically in an OVA-induced murine allergy model. Furthermore, we measured 
antibody titres, T-helper cell differentiation and the expression receptors of the innate 
immunity to assess the influence of Salmonella on the immune response. 
 
Methods 
Bacterial strains and culture conditions 
Salmonella strain MvP455 and plasmids p2096 and p2629 used in this study were obtained 
from Dr. Michael Hensel (Erlangen, Germany) and are described in13-16. MvP455 harbours a 
mutation of recA through stable integration of a GFP/Kanamycin gene cassette which is 
regulated intracellularly by promotor sseA. recA mutants have been described as avirulent 
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and sensitive to the oxidative burst of macrophages17. Plasmids p2096 and p2629 are low 
copy number plasmids that contain either effector protein sseF fused on OVA protein (p2629) 
or on sseG (p2096) as a control (Fig.1). Bacteria were routinely cultured in Luria-Broth (LB, 
MP Biomedicals) and on LB agar (Becton Dickinson) plates containing 50 µg/ml kanamycin. 
For the selection or to maintain plasmids, ampicillin (100 µg/ml) was added.  
 
Bacterial infection of macrophages and allergen expression 
The murine macrophage cell line RAW264.7 (European Collection of Cell Cultures, UK) was 
cultured in Dulbecco`s modified Eagle medium (DMEM, GIBCO) containing 10 % heat-
inactivated fetal calf serum (FCS, PAA/Omnilab) and 1% Antibiotics/Antimycotics (AB/AM, 
GIBCO) at 37°C in an atmosphere of 5% CO2. The cells were suspended in 24-well plates for 
experiments at a density of 5 x 104 cells per well. The infection of RAW264.7 cells with S. 
typhimurium strains was carried out as described in18. The intracellular amount of OVA was 
analyzed by Western blot analysis. For OVA detection rabbit anti-OVA primary antibody 
(Chemicon) and goat anti-rabbit IgG (HRP, Amersham Bioscience) as secondary antibody 
was used. OVA was detected by chemiluminescence using ECL system (Amersham 
Bioscience). 
Animal keeping and mice sensitization  
Female C3H/HeJ mice were purchased from Jackson Laboratory (USA). All mice were kept 
at the Institut für Labortierkunde of University hospital Zurich under specific pathogen-free 
conditions. Animals were used 4-6 weeks of age and were fed with standard mice pellets 
without OVA. All experiments were conducted in accordance with the ethical guidelines of 
Animal Studies Ethics Committee. 
Figure 1. Illustration of the used constructs. The low copy plasmid pWSK29 bears an expression 
cassette which consists of the in vivo activated promoter Pro SseA, the effector protein SseF with 
the chaperon sscB and a gene fragment encoding either the model allergen OVA (p2629) or the 
effector protein sseG (p2096). 
 
pWSK29 
Pro SseA 
sscB sseF OVA M45 
Pro SseA 
sscB sseF sseG M45 
p2629 
p2096 
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A murine model of food allergy as published earlier by Li XM et al19 and Frossard CP et al20 
was used in the experiments. Mice were sensitized orally at days 0, 7, 14, and 21 with 20 mg 
OVA (Sigma) and 10 µg cholera toxin (List Biological Laboratories) in PBS. For bacterial 
treatment, Salmonella were grown over night until mid-log phase. Bacteria were then 
harvested by centrifugation (4500 rpm) and resuspended in PBS. 109 CFU/mouse in a 
volume of approximately 200 µl were given prior each oral sensitization (prophylactical 
approach, Fig. 2a) or after sensitization phase (therapeutical approach, Fig. 2b), using a 
round-tip stainless steel needle. The actual infection dose was always verified by serial 
dilution and subsequent plating on LB-agar plates in the presence of appropriate antibiotic. 
Two groups of control mice were administered either with PBS or with plasmidless bacteria. 
On day 28 (prophylactical approach) and day 70 (therapeutical approach), respectively, all 
mice were challenged by intragastric gavage with 50 mg OVA and observed 30 min until they 
were sacrificed with CO2. Anaphylaxis was graded using a symptom score. Score 0: no 
symptoms; score 1: low activity, randomly scratching, reduction of the symptoms within 5 
min; score 2: considerable low activity, constantly scratching, abnormal breathing, reduction 
of the symptoms within 10 min; score 3: considerable low activity, constantly scratching, 
abnormal breathing, swollen nose, duration of the symptoms > than 10 min; score 4: 
absence of reaction, death. The scoring of the symptoms was performed in a blind manner 
as two individuals unaware of sample identities evaluated scores. 
Figure 2. Experimental protocol: Intragastric OVA sensitization and Salmonella administration. Mice were 
sensitized at day 0, 7, 14, 21 with OVA and choleratoxin. Three groups of mice were fed either with Mvp455 
p2629, Mvp455 p2096 or PBS prior each sensitization step (Fig. 2A) or after the sensitization phase (Fig. 2B). 
Mice were challenged with 50 mg OVA at day 28 and 70, respectively. 
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Feces preparation 
Fecal samples were collected at day 2, 20, 27, 29 (prophylactical approach) and day 0, 16, 
30, 58, 60, 70 (therapeutical approach). Extracts of fecal pellets were prepared as described 
by Marinaro et al.21. In brief, 100 mg of fecal pellets was mixed with 1 ml of PBS containing 
0.1% NaN3 and incubated for a minimum of 2 hours at 4°C. Then the pellet was vortexed for 
10 min. After centrifugation (4000g, 20 min), supernatants were collected and stored at -
80°C. 
OVA-specific immunoglobulin measurement 
We measured levels of OVA-specific IgE, IgG1 and IgG2 in sera after challenge and IgA in 
fecal extracts at different timepoints, using an enzyme-linked immunosorbent assay (ELISA). 
For the assays, plates were coated with 100 µg/ml OVA in coating buffer (pH 9.5) overnight 
at 4°C. After blocking with PBS + 10% FCS for 1h, 100 µl of samples were added to the 
plates. Sera were diluted 1:20 for IgE and IgA, 1:100 for IgG3, 1:1000 for IgG2 or 1:5000 for 
IgG1. Plates were incubated overnight at 4°C. After washing, biotin-conjugated rat anti-
mouse IgG1, IgG2, IgE, or IgA monoclonal antibodies (2 µg/ml; BD Pharmingen) were added 
to the plates for detection of OVA specific immunoglobulin and incubated for 1h at room 
temperature. Streptavidin HRP (BD Pharmingen) was incubated for 30 min as detecting 
reagent (1:1000). The reactions were developed with the TMB substrate (BD OptEIA) and 
stopped with 50 µl 2N H2SO4. The plates were read at 450nm. 
Tissue homogenization and gene expression measurement 
We transferred 30 mg of the frozen lymph nodes to 350 µl RLT buffer (QIAmp RNA Blood 
Mini Kit, Qiagen) supplemented with 1% β – mercaptoethanol and homogenized it using a 
Retsch MM300 mixer mill (Retsch). For total RNA extraction, we used the QIAmp RNA Blood 
Mini Kit (Qiagen) supplemented with RNase-free DNase (Qiagen). For reverse transcription 
(RT), we used 300 ng of total RNA in a final volume of 30 µl and added adequate amounts of 
TaqMan Reverse Transcription Reagents (Applied Biosystems). We performed quantitative 
real-time PCR with 3 µl of RT solution in a final volume of 25 µl and analyzed it with an ABI 
Prism 7700 Sequence Detection System (Applied Biosystems). All primers were ordered as 
pre-developed assays from Applied Biosystems. The gene expression values were 
normalized to the endogenous control 18s rRNA and relative mRNA amounts were 
determined using the comparative Ct (threshold cycle) method according to the 
manufacturer’s instruction (Applied Biosystems). 
Isolation of lymphnode cells and T helper cell determination 
Freshly removed lymphnodes were pooled per group in precooled PBS containing 2% FCS 
(PAA) and kept on ice. The organs were homogenized using a plunger of a 5 ml syringe and 
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a prewet cell strainer with a 100 µm-mesh (Falcon). The cell suspension was centrifuged at 
1400 rpm (10 min at 4°C). To remove the red blood cells, 5 ml sterile lysis buffer (0.15M 
NH4Cl, 10mM KHCO3, 0.1M NA2EDTA, pH 7.2-7.4) was added and the cell solution was 
incubated for 5 min at 4°C. After centrifugation (1400 rpm, 10 min), the cells were once 
washed with PBS + 2% FCS and then diluted in cell culture medium (RPMI1640, GIBCO + 
10% FCS + 50 µg/ml gentamicin). To determine the T helper cell populations (Th1, Th2, 
Treg) in lymphocytes, intracellular staining was carried out, using the mouse Th1/Th2 flow 
panel and the mouse regulatory T cell staining kit (both eBioscience) according to the 
manufacturer’s protocol. The FACS analysis was done in the flow cytometer FACSCalibur 
(Becton Dickinson). As a control for unspecific binding, isotype controls were used: rat IgG2a 
for FITC and PE or rat IgG1 for APC (eBioscience). Isotype coated cells were utilized for the 
settings of the FACSCalibur. 
 
Results 
Verification of OVA synthesis  
Prior to the in vivo experiments, mouse macrophages were infected with Salmonella strain 
MvP455 harbouring either OVA encoding plasmid p2629 (Salmonella OVA+) or the control 
plasmid p2096 (Salmonella OVA-) to verify the OVA production. Western Blot analysis have 
shown a clear amount of intracellular OVA (Figure 3 and 16).  
 
Oral challenge to OVA 
To investigate whether Salmonella strain MvP455 p2629 expressing OVA reduce the 
severity of allergic reactions, we administered bacteria orally to mice before each 
sensitization step (prophylactical approach, Fig. 2A) or after sensitization phase 
(therapeutical approach, Fig. 2B) and challenged them with a high dose of OVA. In the 
prophylactical approach the assessed symptom score showed no differences between the 
groups PBS and p2096, which both had a mean score of 2, but a reduced mean score of 0.9 
for p2629 (Fig. 4A). Also for the therapeutical approach, mice treated with Salmonella p2629 
show the least allergic symptoms (mean: 0.8) compared to the control groups (PBS mean: 
1.3; p2096 mean: 2; Fig. 4B).  
Figure 3. OVA detection in vitro. Mouse 
macrophages were infected with Salmonella 
strain MvP455 harbouring either OVA-
encoding plasmids p2629 or control plasmid 
p2096. The intracellular amount of OVA was 
analyzed by Western blotting.  
OVA 
MvP 455 p2096  
negative control 
MvP 455 p2629  
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OVA-specific mucosal IgA in feces 
To investigate the OVA-specific IgA levels in the gut, feces samples were collected at 
different timepoints and pooled per mouse group for further OVA-specific IgA analysis. The 
OVA-specific IgA levels in mice treated prophylactically with Salmonella or PBS increased 
over time (Fig. 5A). However, in both approaches mice treated with Salmonella expressing 
OVA had increased levels of OVA-specific IgA at day of challenge (prophylactical approach 
OD 1.51 ; therapeutical approach OD: 1.1; Fig. 5A, B) compared to that of the controls 
(prophylactical approach: PBS OD 0.96; p2096 OD 1.27; therapeutical approach: PBS OD 
0.37; p2096 OD 0.67, respectively). 
Levels of OVA-specific IgG1, IgG2a/b and IgE in sera 
For the measurement of OVA-specific IgG1, IgG2a/b and IgE, serum of mice was pooled per 
group after challenge. The levels of OVA-specific IgG1 and IgG2a/b in the group of mice 
treated with Salmonella expressing OVA were higher in the prophylactical approach (Fig. 5C, 
E) compared to the control groups, but not in the therapeutical approach (Fig. 5D, F). By 
contrast, in the therapeutical approach mice treated with Salmonella OVA+ showed reduced 
OVA-specific IgE levels (Fig. 5G, H). 
Levels of T-helper cell population in lymphnodes 
To determine the T-helper cell populations (Th1, Th2, and Treg) in lymphnodes, lymphnode 
cells were pooled per mouse group and stained for IL-4, IL-2 and IFN-γ or CD4, CD25, 
FOXP3, respectively, and analysed by flow cytometry. In the prophylactical approach, mice 
PBS PBS p2096 OVA- p2096 OVA- p2629 OVA+ p2629 OVA+ 
Figure 4. Assessed symptom scores after challenge with OVA. Each square/triangle/point corresponds to one 
mouse. Scoring system: Score 0: no symptoms; score 1: low activity, randomly scratching, reduction of the 
symptoms within 5 min; score 2: considerable low activity, constantly scratching, abnormal breathing, reduction of 
the symptoms within 10 min; score 3: considerable low activity, constantly scratching, abnormal breathing, 
swollen nose, duration of the symptoms > than 10 min; score 4: absence of reaction, death. 
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treated with Salmonella expressing OVA showed reduced levels of IL-4, IL-2 and IFN-γ 
positive cells compared to the control groups (Fig. 6A-C). The levels of CD4+CD25+FOXP3+ 
positive cells were higher compared to the PBS group and slightly higher compared to p2096 
(Fig. 6D). In the therapeutical approach, the amount of IL-2 and IL-4 positive cells was higher 
in both Salmonella treated groups (p2629 and p2096) compared to the PBS group (Fig. 6E, 
F). There was no difference in the PBS group and the mice treated with Salmonella 
expressing OVA for CD4+CD25+FOXP3+ positive cells, whereas a decreased amount was 
observed for p2096 (Fig. 6G). 
Expression of Toll-like receptors in cells of lymphnodes 
The relative gene expression of different TLRs is presented in Figure 7A (prophylactical 
approach) and 7B (therapeutical approach). The group Salmonella p2629 (OVA+) showed a 
≥ 0.5-fold decrease for TLR2 and TLR8 (prophylactical approach) and TLR2, TLR7, TLR9 
(therapeutical approach) compared to the group Salmonella p2096 (OVA-) and PBS. TLR7 
(prophylactical approach) and TLR8 (therapeutical approach), respectively was only slightly 
reduced. CD14 was as well reduced in mice treated with Salmonella expressing OVA, 
however, only in the prophylactical approach. No differences were observed for TLR5 (data 
not shown). 
 94 
 
 
 
 
C D 
Figure 5. Antibody titres were measured in pooled sera and feces of each mouse group by enzyme-linked 
immunosorbent assay and presented as optical density. Serum was collected after challenge at day 28 
(prophylactical approach) and 70 (therapeutical approach), respectively. Feces was collected at different 
timepoints during the experiment.  
G H 
B A 
E F 
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Fig. 6F. IL-2 positive cells Fig. 6E. IFN-γ positive cells 
Figure 6. Flow cytometry of IL-2, IL-4, IFN-γ and FoxP3 positive cells of lymphnodes. Cells were analyzed after 
challenge at day 28 (prophylactical approach, Fig. 6A-D) and day 70 (therapeutical approach, Fig. 6E-H), 
respectively. The percentage of IL-2, IL-4, IFN-γ positive cells are referred to the amount of viable cells. FoxP3 
positive cells are referred to the amount of CD4+ and CD25+ cells. 
Fig. 6G. IL-4 positive cells Fig. 6H. FoxP3 positive cells 
Fig. 6D. FoxP3 positive cells Fig. 6C. IL-4 positive cells 
Fig. 6A. IFN-γ positive cells Fig. 6B. IL-2 positive cells 
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Discussion 
Combined intake of microorganisms and low amounts of allergen is a possible method to 
prevent or treat food allergies. We used Salmonella enterica serovar Typhimurium as live 
carrier for the expression of the model allergen ovalbumin fused on the effector protein sseF. 
The symptom scores indicated that mice treated with bacteria releasing OVA have less 
anaphylactic symptoms in a prophylactical as well as a therapeutical approach. These results 
are further based on elevated IgA levels in feces and decreased expression of Toll-like 
receptors in lymphnodes. IgA is predominantly found at mucous membrane surfaces and 
provides an important line of defense against bacteria and viruses, however little is known 
about the role of IgA in food allergy. Eigenmann et al has recently shown in a similar food 
allergy model with prophylactic administration of two different attenuated Salmonella strains 
a higher allergen-specific IgA in feces22 although these bacteria did not express the allergen. 
Our results show also increased OVA-specific IgA levels in mice treated with not OVA-
expressing Salmonella, however the titres were clear increased and the anaphylactic 
symptoms considerably reduced in the group treated with Salmonella expressing OVA. It 
seems that allergen-specific IgA prevents adherence and penetration of OVA and thereby 
reduces immune inflammatory responses through the mucosal epithelium. Bottcher et al 
observed in a prospective 2-year study with new-born infants that high levels of secretory IgA 
were found to be increased in sensitized but clinically tolerant infants suggesting that high 
levels of secretory IgA may protect against development of allergy23. However, pre-treatment 
of mice with Bifidobacterium bifidium, Lactobacillus acidophilus, Bifidobacterium lactis and 
Lactobacillus acidophilus together with Bifidobacterium lactis before OVA sensitization was 
Figure 7. Relative gene expression of different TLRs in lymphnode cells. Expression of mRNA of the 
indicated TLRs was measured by real-time PCR, RNA yield differences were calculated using 18s RNA as 
endogenous control and the comparative CT method for relative quantification. Bars represent the mean 
values for each group; error bars represent standard errors. A: Prophylactical approach; B: Therapeutical 
approach. 
A B 
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found to lead to a decreased OVA-specific IgA level in fecal samples24,25. This indicates that 
bacteria, particularly the intracellular or extracellular living in the gut influences the IgA 
response. 
The signalling mechanisms of the innate immune system may control susceptibility to allergy. 
TLRs are pattern recognition receptors which recognize highly conserved microbial 
structures and thereby initiate and guide the immune responses. In both approaches the 
expression of different TLRs was decreased in mice treated with Salmonella expressing 
OVA. We presume that the repeated bacterial stimulation developes oral tolerance and may 
lead to less inflammatory response, what may reduce the anaphylactic symptoms.  
Linked to the use of attenuated Salmonella strains, different studies described an increased 
Th1 activity, as indicated by IFN-γ production from antigen-stimulated T cells, high amount of 
antigen-specific IgG2a levels and decreased antigen-specific IgG1 levels in serum22,26-29. Our 
data are not completely consistent of that since we measured only in the therapeutical 
approach more IFN-γ positive cells in mice treated with Salmonella expressing OVA and the 
levels of allergen-specific IgG1 and IgG2a/b in serum behave the same trend. These 
differences may based on the used mouse strain C3H/HeJ which bears a spontaneous 
mutation in the tlr4 gene. TLR4 is the receptor for lipopolysaccharid (LPS)30 which is the main 
component in the outer membrane of Gram-negative bacteria, such as Salmonella and 
mediates the expression of pro-inflammatory cytokines, such as TNF-a and IL1231,32 and the 
induction of adaptive immune response. Through this mutation the induction of adaptive 
immune response and the production of IgG may be disordered. Furthermore, Husseiny et 
al18 compared the humoral immune response against OVA in mice, immunized with the 
conventional and extensively used auxotrophic aroA or the sseC carrier strain deficient in 
SPI2 gene. Both strains were modulated to express OVA either constitutive or regulated. 
They observed a pronounced increase in OVA-specific IgG titers after immunization with the 
sseC strain, especially if the OVA gene expression was regulated. This indicates that the 
bacteria strain as well the type of promoter which regulates the antigen expression influence 
the immune response. Further analysis with other mouse and bacteria strains are still 
needed to understand the underlying immunological mechanisms. However our results 
provide an indication that the use of Salmonella, modified genetically to express an allergen, 
may be a suitable tool to prevent and treat food induced allergy.  
 
Contribution to this work 
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Lauener at the Childrens's Hospital Zürich. I wrote the licenses for animal testing and I 
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In 1948 first adverse reactions to corn, wheat, milk, egg and other frequently ingested food 
were reported1. The prevalence of food allergies among children and adults appears to be 
rising in Western countries, and there are indication of an increasing prevalence of new food 
allergy, such as kiwi allergy2 and sesame seed allergy3. The most observed allergic reactions 
are against egg and milk and certain food allergies seems to be specific for geographic 
regions, e.g. bird nest soup allergy in Singapore, royal jelly allergy in Hong Kong, and 
mustard allergy in France4. The reasons for food allergy are not defined, however genetic 
and environmental exposition factors are involved in the development and new therapeutic 
and prophylactical mechanisms beside avoidance of allergens are needed. Desensitization is 
a well established method against insect sting allergies or hay fever and there are a growing 
number of oral immunotherapy studies, in which a food allergen is ingested in gradually 
increasing amounts over month. The success rates mainly for egg and milk allergy vary and 
the procedures are not without side effects, including systemic allergic reactions5-7.  
 
In our considerations concerning the application of desensitization in food allergies, the 
crucial question was how the release of food allergens occurs on-site where the contact to 
immune cells is given, primarily in the gut-associated lymphoid tissue (GALT) which is 
constantly exposed to a variety of antigens and must induce a state of nonresponsiveness 
(mucosal tolerance) or in case of pathogen invasion elicit a strong T- and B-cell response. 
The choice to use Salmonella enterica serovar Typhimurium as living vectors offered two 
convincing advantages: First, these bacteria prefentially enter M cells in the gut, which 
transport them to the lymphoid cells (T and B) in the underlying Peyer`s patches and second, 
they are studied intensively for vaccination strategies, therefore attenuated strains are 
investigated and available. The use of attenuated Salmonella typhimurium, modified to 
deliver the allergen OVA had shown in fact a beneficial effect against OVA-induced food 
allergy in a prophylactical as well as in a therapeutical approach. Therefore, these results 
suggest that there is presumably a possibility to treat food allergy with the method of 
desensitization. However, similar to other strategies (modified protein vaccine, plasmid DNA 
encoded vaccines, sublingual/oral immunotherapy etc.) the use of Salmonella typhimurium in 
food allergy shows still limitations which have to be discussed and resolved.  
Although we have seen reduced anaphylactic symptoms in mice treated with Salmonella 
expressing OVA the underlying immunological mechanism is still unclear. Reduced 
expression of receptors of the innate immunity and elevated levels of CD4+CD25+FOXP3+ 
cells in groups of mice which show less anaphylactic symptoms provides an indication of oral 
tolerance but further detailed work in this field is necessary. Another phenomenon which is 
already described in literature and partly observed in in vitro analysis by ourselves concerns 
the combination of attenuation, allergen coding (chromosomal or by plasmid) and allergen 
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regulation (constitutive or intracellular active). Although a chromosomal gene integration is a 
stable variant to maintain the gene, the lower amounts of allergen due to the single gene 
copy is disadvantageous8. We observed a stronger allergen expression by the constitutive 
promoter, however the use of intracellular activated promoters was described to stimulate the 
immune system more effectively9-11 compared to the constitutive one. The optimal interplay 
between gene regulation and location has to be further studied in in vitro as well as in vivo 
models. Also the kind of attenuation regarding to safety needs additional investigations, 
namely the guarantee for local bacterial occurrence in the gut and the exclusion of bacterial 
persistence.  
 
Finally, it should be considered if this method is suitable to use for other food allergies, 
especially peanut and/or tree nut allergies, which affect over 1% of Americans and are 
responsible for a disproportionate number of deaths12. In theory, gene exchange of the 
allergen should be possible, however it is known that peanut allergy is at least in part 
genetically determined. This form of allergy is about 7-fold more likely to occur in a child with 
parents or a sibling who is peanut allergic compared to the general population risk13 and in 
case of monozygotic twins the likelihood for peanut allergy is 64% if the twin sibling is 
affected14. However, since specific genes have not been identified, it is difficult to estimate if 
the genetic predisposition countervails the attempt of desensitization. In view of our results of 
the PASTURE-Study (Chapter A1-A3) a therapy in children with genetic predisposition to 
food allergy should probably be made early in life when the immune system and the immune 
tolerance is developed.  
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Abbreviations 
AICDA   activation-induced cytidine deaminase 
ALEX   ALlergy and EndotoXin 
APC   antigen presenting cell 
AT   Austria 
BIR   baculovirus inhibitor domain 
CARD   caspase recruitment domain 
cDNA   complementary DNA 
CB   cord blood 
CD   cluster of differentiation 
CH   Switzerland 
CI   confidence interval 
CpG   cytosin-phosphatidyl-guanosin  
CIITA   class II transactivator 
CT   cholera toxin 
Ct   threshold cycle 
DC   dendritic cell 
DE   Germany 
ERK   extracellular signal-regulated kinase 
FOXP3  forkhead box P3 
FI   Finland 
FR   France 
Ig   immunoglobulin 
IL   interleukin 
ILT   immunoglobulin-like transcripts  
IKK   inhibitor of nuclear factor-B (IB)-kinase complex 
IRAK   IL-1R-associated kinase 
IRF   interferon-regulatory factor 
ITAM   immunoreceptor tyrosine-based activation motifs 
JNK   c-Jun N-terminal kinase 
LBP   LPS-binding protein 
LPS   lipopolysaccaride 
LRR   leucine-rich repeat 
MAPK   mitogen-activated protein kinase 
MHC   major histocompatibility complex 
mRNA   messenger ribonucleic acid 
MyD88  myeloid differentiation primary-response protein 88 
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NEMO   NF-κB essential modifier 
NF-κB   nuclear factor-κB 
NLR   Nod-like receptor 
OD   optical density 
OVA   ovalbumin 
PAMP   pathogen-associated molecular pattern 
PARSIFAL Prevention of Allergy Risk factors for Sensitization in children related to 
Farming and Anthroposophic Lifestyle 
PASTURE  Protection against Allergy: Study in Rural Environments 
PI3K   Phosphoinositide 3-kinase 
P/I   Phorbol 12-myristate 13-acetate (PMA) /Ionomycin  
PMA   Phorbol 12-myristate 13-acetate 
PRR   pattern recognition receptor 
PYD   pyrin domain 
SARM   steril α and armadillo motifs 
SIGIRR  Single Ig IL-1–related receptor 
SOCS   suppressor of cytokine signalling 
SPI   Salmonella pathogenicity islands 
T3SS   type III secretion system 
TCR   T-cell receptor 
Th   T-helper cell 
TIR   Toll/IL-1R homology 
TIRAP/MAL  TIR-associated protein 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
TOLLIP  Toll-interacting protein 
TRAF   TNFR-associated factor 
TRAILR  TNF-related apoptosis-inducing ligand receptor 
TRAM   TRIF-related adaptor molecule 
Treg   T regulatory cell 
TREM   triggering receptors expressed by myeloid cells 
TRIF/TICAM1  TIR-domain-containing adaptor protein-inducing IFN-β 
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